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Abstract 
 
Background: Image-guided radiation therapy (IGRT) has drastically enhanced the 
accuracy of radiation delivery and has developed as the new worldview for patient 
positioning and target localization in radiotherapy. Using a Kilo Voltage Cone Beam 
Computed Tomography (KV CBCT) approach, three dimensional (3D) volumetric 
patient anatomy is available for patient positioning for each fraction. This helps in 
adaptive planning as seen in newly developed scenarios that contributes to better care for 
patients. 
 
Although the addition of the kV CBCT imaging modality into radiotherapy increases 
treatment precision[1], it also increases the patient dose without it being displayed on the 
planned dose[2, 3]. Separately estimating the CBCT dose is considered important to 
achieve an accurate planned dose [4] to avoid patient doses exceeding critical organ 
threshold levels. In most of the planning systems however, the effect of CBCT dose is 
neglected as it is thought to be negligible in comparison with Mega Voltage (MV) therapy 
dose[5].  
Aim: This project aims to determine the patient doses from CBCT during a selected 
number of radiotherapy procedures. This is achieved through direct measurement 
radiation dose in a phantom and through mathematical modelling utilising existing 
software used in diagnostic radiology dosimetry. A second aim then is to compare these 
methodologies.  
Methods: The evaluation of CBCT doses was achieved through two different 
methodologies. In the first method Thermoluminescent Dosimetry (TLD) measurements 
were performed using a Rando phantom on a VarianTM On Board Imager (OBI) Linac 
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system utilising manufacturer specified CBCT protocol parameters for Standard Head 
and Pelvis Spot CBCT protocols. For this project TLD measured values were regarded as 
the base line values. In the second method, the Monte Carlo code PCXMCTM was used in 
rotation mode utilising ExcelTM. Additional modelling was required due to the fact that 
PCXMC uses a flat filter while CBCT units utilise shaped filters such as the Bow-tie 
filter. This involves the determination of procedure protocols and dosimetric parameters 
associated with each procedure investigated. For the units examined at Canberra Hospital 
the manufacturer specified the CBCT protocol parameters. Dosimetric parameters included 
quantifying the effect of the bow tie filter and general beam output. The effect of patient size 
was investigated as dose-modifiers through changes in the PCXMC patient model, including 
the relation between specific critical organ doses and patient size.  Finally, the organ doses 
obtained through each of the two methodologies were compared. 
 
Results:  The CBCT doses for critical organs identified by the standard head and pelvis spot 
protocols were measured using TLDs and calculated through PCXMCTM simulations. For a 
full radical brain series of treatment fractions, the highest estimated total organ dose is 
180 mGy for the parotid gland. For a full bladder series of treatment fractions, the highest 
estimated total organ dose is 230 mGy in the uterus. For a full intact prostate series of 
treatment fractions, the highest estimated total organ dose is 810 mGy.  
 
Comparing the TLD measured results and PCXMCTM simulated results, it can be seen 
that the dose to the parotid gland matches within 10%, whereas the spinal cord dose 
comparison shows almost a 30% difference. It is also to be noted that certain organs 
cannot be properly compared due to the absence of holes in some of the actual organ 
positions in the phantom.  
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The comparison of PCXMCTM software simulated results for standard Rando man 
phantom and standard Australian man phantom shows a consistent variation between 
organ doses ranging from 5% to 18 % with lower doses seen in the standard Australian 
man. This highlights the fact that as the patient size reduces dose received by the patient 
increases for a given set of exposure parameters. 
 
Discussion:  
When estimating the total doses due to CBCT protocols, difficulties were encountered in 
that the number of radiotherapy fractions for a given radiotherapy treatment regime varied 
greatly. The total dose contribution due to the CBCT protocol is currently ignored in the 
calculation of the clinical radiotherapy treatment dose. The methodology developed and 
utilised in this thesis shows that there is a small, but measurable, contribution to the organ 
dose from the CBCT protocols performed during a typical radiotherapy treatment regime. 
The highest organ dose was for the uterus in pelvic-related radiotherapy treatment where 
up to 6% of the threshold dose might be achieved through the use of CBCT alone. 
 
The patient size calculations demonstrated that with the current use of fixed radiographic 
factors, as the size of the patient increases the total dose to critical organs reduces. 
However, the increasing size of the patient will simultaneously decrease the quality of the 
image when measured in terms of the contrast to noise ratio. Similarly, if such images are 
clinically adequate then implementing variable radiographic factors would see a 
corresponding decrease in the total dose received by smaller patients.  
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Conclusion: 
The results presented in this thesis demonstrate that there is a small, yet significant, total dose 
contribution due to the current CBCT protocols typically used as part of radiotherapy 
treatments in cancer clinic today. It was shown that in some cases the additional dose should 
be considered in the treatment planning process due to possible impacts on organ threshold 
values. The additional CBCT dose will of course, add to the increased risk of secondary 
cancers, but this is a very minor impact. 
 
The results also indicate that the radiation dose varies significantly with both patient size and 
tumour position for both standard head and pelvic spot scanning protocols. Therefore, a 
recommendation arising out of this thesis work is that the current practice of using fixed scan 
parameters, independent of patient size, be reconsidered to incorporate patient-specific 
imaging protocols. Especially for the case of paediatric patients who will otherwise receive a 
higher CBCT related dose. 
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1 Introduction 
 Background 
Radiotherapy, is a type of treatment using ionizing radiation, generally as part of cancer 
treatment to control or kill malignant cells [6]. Radiation therapy aims to give high doses 
to malignant cells to cure or control the growth of these malignant cells and low doses to 
normal healthy tissues. Radiotherapy can be used before or after other treatments to make 
them more effective. In some cases, if a cure is not possible, radiation therapy may be 
used to reduce cancer symptoms and prolong a good quality of life. 
 
Progress in radiotherapy is guided by the need to realize improved dose distributions, i.e. 
the ability to reduce the treatment volume toward the target volume while still ensuring 
coverage of that target volume in all dimensions. Poor ability to control the tumour's 
location limits the accuracy with which radiation can be delivered to tumour-bearing 
tissue [7]. In Radiotherapy strategies to make sure that the accurate delivery of treatment 
dose localized to the tumour are required. The rapidly evolving imaging technologies 
have led to substantially greater accuracy and precision of radiation delivery to the target, 
with patient positioning and target localization in radiotherapy now of greater critical 
importance [8]. Radiation therapy machines are equipped with imaging technology to 
allow imaging of the tumour before and during treatment. This type of radiation delivery 
is known as Image Guided Radiation Therapy (IGRT). By comparing these images to the 
reference images taken during simulation, the patient's position and/or the radiation 
beams may be adjusted to more precisely target the radiation dose to the tumour. To help 
align and target the radiation equipment, some IGRT procedures may use fiducial 
markers, ultrasound, MRI, x-ray images of bone structure, CT scan, 3-D body surface 
mapping, electromagnetic transponders or coloured ink tattoos on the skin. 
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Historically, megavoltage “port films” were used as an early form of IGRT but lacked 3-
D visualization of soft tissue targets and often was not applied to every fraction. Planar 
MV imaging provides limited localization by using “bony anatomy”[9]. With planar MV 
images however, it is difficult to correct for tumour motion relative to bony anatomy 
between fractions and this causes a loss of tumour control and increased normal tissue 
irradiation[10]. However, the tumour being treated is often a mobile soft tissue mass 
within the body, and patient repositioning based on bony landmarks alone is subject to 
error. Addressing these uncertainties, the target coverage inevitably irradiates a large 
volume of normal tissue unnecessarily in the process. With improving soft tissue 
localization and increasing frequency of imaging and correction, uncertainty is mitigated 
allowing correspondingly reduced margins and safer administration of curative radiation 
doses.  The need for this improved accuracy and precision has been amplified by ongoing 
advances in radiation planning and delivery that permit much more conformal dose 
distributions with sharper dose gradients.   
  
With a kV cone beam CT (CBCT) approach, 3D volumetric visualisation of patient 
anatomy is available for patient positioning for each treatment fraction. The 3-D 
volumetric visualization helps in reducing the inter-fractional motion as well as tumour 
visualisation and therefore is key to the adaptive planning process. The use of kV CBCT 
enables the patient position to be adjusted to ensure accurate localisation of the soft tissue 
tumour rather than using the bony anatomy as a surrogate[11, 12]. 
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Although the addition of the kV CBCT modality into radiotherapy increases treatment 
precision[1], it also raises some points to consider. Such considerations include (1) any 
increase in the patient dose without it being displayed as part of the planned dose[2, 3], 
and (2) kV CBCT dose variation based on the patient size. From a radiation safety 
perspective, the optimisation and justification of the radiation dose, and the radiation dose 
due to patient size variation, is highly important. To quantify any additional dose that 
should be added to the treatment dose, it is important to measure the cone beam CT dose 
separately. From a radiation safety point of view this additional dose can lead to a 
localised dose to some of the critical organs that may fall into the treatment regime. If 
planning systems neglect the effect of the CBCT dose [5] and the effect of patient size, it 
is important that OAR doses be accurately determined for optimisation. Also, to ensure 
that local doses are estimated accurately giving a better awareness of the imaging dose 
that is being deposited in the patient’s body. This project aims to determine the patient 
doses from CBCT during the radiotherapy procedures, through measurement and 
modelling, to make sure that the local doses due to CBCT doses are not pushing the 
radiotherapy doses beyond the accepted organ threshold levels. 
 
 Project outline 
1.2.1 Aim 
The aim of the project is to determine the patient dose (to a standard patient) from 
commonly performed Cone Beam Computed Tomography (CBCT) imaging procedures 
at the Radiotherapy centre at The Canberra Hospital (TCH) using two techniques and 
relating these to current radiation safety practice.  
1) PCXMCTM Calculation 
2) TLD Measurements 
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1.2.2 Objectives 
1. To determine the detail and extent of different CBCT protocols used at TCH.  
2. Review the relevant literature on (i) CBCT dosimetry formalism and (ii) 
clinical determination of CBCT dose. 
3. Investigate the feasibility of phantom dosimetry. 
4. Measurement and calculation of patient doses using CT simulation software 
including doses to organs at risk with an appropriate uncertainty estimated. 
5. Make recommendations on improvements to current practice, and for further 
work, to increase the extent of knowledge in the area. 
1.2.3 Scope of the Project 
As a student of the medical radiation physics discipline I had the experience of working 
in a medical physics department, which prepared me for competitive entry into a medical 
physics residency program.  
  
Benefits for the clinical department included increased knowledge of patient doses 
surrounding the CBCT procedures commonly carried out and an updating of the 
associated procedural documentation. Knowledge of CBCT patient dose can be utilized 
in the treatment planning of patients undergoing radiotherapy to make radiotherapy 
treatments more accurate. 
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2 Literature Review 
 
In section 2.1 a detailed discussion on how the CBCT scanner has developed over the 
years is provided, also covering a description of the main components of a common 
CBCT system and its working principle along with the importance and problems 
encountered while using the CBCT systems in radiotherapy. In section 2.2 different 
methodologies used for patient dose estimation, various patient dose determination 
studies and different dosimetric techniques including TLDs and various simulation 
softwares are discussed in detail. 
 CBCT in Radiotherapy 
2.1.1 Developmental History of CBCT and its main applications 
When researching the history of radiation applied to medical science it all points to a date, 
the “8th of November 1895”, which is the day Wilhelm Conrad Roentgen discovered and 
named the X-ray[13]. This discovery led to the emergence of a new medical science 
precipitating the creation of sophisticated medical equipment based on radiation that 
covers both the diagnosis of human disease and its treatment. Without any doubt, we can 
now say that radiation plays a vital role in maintaining human health.  
One of the pioneers of conventional tomography was E. M. Bocage (1922). As early as 
1921, Bocage described an apparatus to blur out structures above and below a plane of 
interest[14]. Along with this progression of knowledge at the time, there have come many 
developments in the field of radiation related instrumentation. The invention of Computed 
Tomography (CT) scanner is considered to be a revolutionary example[15].  
The invention of the CT occurred in 1972 by British engineer Godfrey Hounsfield of EMI 
Laboratories, England, and South Africa-born physicist Allan Cormack of Tufts 
University[16], Massachusetts. This changed the face of medical treatment as CT 
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imaging, demonstrated that one could provide views of soft tissue, bone, muscle, and 
blood vessels, without sacrificing clarity when compared to normal planar X-ray 
techniques. Soon it became the tool for the planning of surgeries, and biopsies as well as 
radiotherapy treatments.  
 
The first developed CT scanner, EMI mark 1 was used to image the head only, as it only 
had a small opening through which the scan was carried out. The first Tomographic 
examination of an actual patient was carried out on first of Oct 1971[15]. Soon after the 
announcement of the development of the CT both Hounsfield and A.M Cormack were 
awarded with the Nobel prize in 1979 for their contributions[17]. 
 
Following this development people were in search of a diagnostic tool which could help 
in the rapid 3D acquisition of images with relatively low dose, high spatial resolution and 
visualization of high contrast studies in the head and neck and other anatomical 
regions[18]. 
 
The term cone beam refers to the cone shaped X-ray beam from the source. The first 
developed CBCT technology was intended to be used in angiography in 1982[19]. During 
the early stages of CBCT development most of its work was focussed on the angiography 
applications. During the late 1990’s the commercially developed CBCT machines were 
available for use in dentistry[20, 21]. The advantage of CBCT system was the reduced 
time of acquisition and low dose in comparison with the normal CT modality[22] even 
though the image quality was less attractive.  
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2.1.2 Introduction of CBCT into Radiotherapy 
In the case of radiotherapy, the localization of tumours is required to ensure accurate 
delivery of treatment. It is difficult to use the MV planar portal-image generated by the 
Linear accelerator (LINAC) system as it provides only a limited projection image of bony 
anatomy which does not discriminate between the low contrast of soft tissue and the 
tumour [10]. Hence, using MV portal-imaging, it is difficult to correct for any tumour 
motion between fractions. In order to ensure the desired tumour control is achieved, it is 
necessary to increase the target volume margins. A subsequent increase in normal tissue 
irradiation is therefore unavoidable. MV-CBCT is a 3D imaging technique and therefore 
has advantages over the MV planar portal-image technique and is quite adequate for 
image guidance based on the bony anatomy. To obtain better soft tissue contrast, and 
thereby understand and track tumour motion with MV CBCT, higher doses need to be 
delivered. As a result there is a marginal increase in the local dose that can lead to further 
complications [23].   
 
The search for an IGRT imaging modality which can easily differentiate between normal 
tissue and malignant cells and can deliver low imaging doses led to the invention of kV 
CBCT. Research to develop CBCT based LINAC’s was started in 1992 and the first 
LINAC mounted CBCT was produced in 1999[19]. Since this time, the CBCT technology 
has improved its capabilities for use in the radiotherapy field. Currently kV CBCT has 
become the common IGRT tool in radiotherapy. At present, there are 2 dominant 
manufacturers of CBCT systems built into MV radiotherapy treatment systems: 
1) VarianTM on Board Imager (OBI) (VarianTM Medical Systems, USA) 
2) ElektaTM X-ray Volume Imaging (XVI) (ElektaTM Oncology systems, UK) 
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The VarianTM and ElektaTM systems are kV imaging modalities (30-140 kV) in which a 
kV X-ray source and detector are attached perpendicular to the treatment beam such that 
the CBCT source and detector are aligned to each other.  
2.1.3 Main Components of Cone Beam CT System. 
The main components of a CBCT system can be divided into two major sections:  
1) Hardware 
2) Software  
 Hardware 
The main hardware components associated with the CBCT systems are an X-ray source 
assembly, beam shaping assembly  and an image receptor unit sometimes called an 
Imager and [21]. 
a) X- ray Source 
The x-ray sources for a kV CBCT is a diagnostic x-ray tube, similar to those used in 
conventional CT. The VarianTM OBI system consists of a kV X-ray source. It is mounted 
on a VarianTM LINAC at 90 degrees with respect to the treatment beam direction. The 
VarianTM setup includes a standard 60-140 kV X-ray tube with a mAs of capability up to 
2 mAs per projection. The tube is oil cooled with a rotating anode and a 140 Rhenium-
tungsten facing bonded onto a molybdenum with a graphite backing. It has two focal 
spots available at 0.4 mm and 0.8 mm. More details about the VarianTM X-ray source is 
specified in the appendix 1. The ElektaTM CBCT system uses a 40-130 kV X-ray tube 
with a mAs per projection varying from 0.1 to 3.2 mAs. A sample image of an X-Ray 
tube is shown in figure (1). 
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Figure 1 Typical X- ray Tube assembly [reproduced from 2006 Merriam -Webster, Inc] 
 
b) Beam shaping assembly 
Once the beam exits the housing window it is modified by fixed and moveable 
collimators, additional filtration, and a detachable beam shaping assembly. VarianTM has 
two beam shaping assemblies that each use a specially designed filter called a full bow-
tie or a half bow-tie filter. The bow-tie filter, composed of an unknown alloy, is designed 
in such a way that by increasingly attenuating the beam at the periphery of the patient, 
where attenuation is lowest, a relatively constant output across each projection at the 
detector is achieved. Additionally the low energy X-rays are filtered to reduce the beam 
hardening effect[24]. A reduction of exposure at the edge of the patient will also reduce 
the scatter to primary ratio. A representative image of a Bow-tie filter used by the 
VarianTM system is shown in figure 2. 
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Figure 2  Half and full Bow-tie filter design used by VarianTM LINACs 
 
c) Imager 
Usually the image receptor is a flat panel digital detector (flat-panel imagers- FPIs) used 
for imaging in the cone beam CT system. Some of the most widely used FPIs are made 
up of amorphous silicon/selenium thin film transistor (TFT) technology. The advantage 
of these detectors is that they provide a large area image with a fast readout. A sample 
image of amorphous selenium FPI is shown in figure 3. 
 
Figure 3 A typical Amorphous selenium flat panel detector[25] 
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2.1.4 Basic Principle of CBCT 
In the case of CBCT imaging, the X-ray source and 2D detector panel rotate around the 
patient. The X-rays transmitted through the patient are detected by the detector. A variety 
of technologies are used for the imaging detectors including flat panel detectors or an 
image intensifier combined with a charge coupled device (CCD). During rotation around 
the patient, the detector acquires 2D image projections. Each acquired image is called a 
basis image. The set of basis images are collected into a set of so-called projection 
data[20]. The acquired projection data is reconstructed with the help of complex 
mathematical algorithms (see below), to produce a volumetric representation of the body. 
A schematic representation of cone beam CT imaging is given in figure 4. 
 
 
       
Figure 4 Schematic representation of a CBCT system 
 
X ray source 
Cone of X-rays
Detector 
   © J Can Dent Assoc 2006; 72(1); 75-80 
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Two major categories of reconstruction methods are applied to CT reconstruction being 
analytical and iterative reconstruction and these can be in either 2 or 3 dimensions. There 
are many types of analytical reconstruction. The most commonly used analytical 
reconstruction methods on commercial CT scanners are all in the form of filtered back-
projection (FBP), which uses a 1D filter on the projection data before back-projecting 
(2D or 3D) the data onto the image space. In the case of iterative analysis, image 
reconstruction starts with an assumption and compares it with the measured values, 
making corrections to bring the two into agreement, and repeats the process over and over 
until the measured and assumed values are the same or within the acceptable limits.  
 
When it comes to CBCT, the first and most widely used  three dimensional image 
reconstruction from cone-beam projections measured with a circular orbit of the x-ray 
source is the algorithm of Feldkamp, Davis, and Kress (1984) [26]. The FDK technique 
comprises the steps of weighting, filtering and back-projection of data for each projection 
measurement over the reconstruction volume. The weighting of the projection data is 
performed with a point-by-point multiplication by a pre-calculated 2D array. 
 
2.1.5 CBCT in radiotherapy? 
Image-guided radiation therapy (IGRT)[27] has dramatically increased the precision of 
radiation delivery and has developed as the new worldview standard for patient 
positioning and targeted localization in radiotherapy. With a kV cone beam CT approach, 
3D volumetric patient anatomy for patient positioning is being generated during each 
fraction. This helps in adaptive planning as newly acquired scenarios also helps to update 
the dose distribution to the benefit of the patient. 
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In Radiotherapy, it is important to have  strategies for making sure the accurate delivery 
of treatment to the localized tumour are required[28]. Using planar MV imaging 
techniques it is difficult to differentiate tumour and non-tumour tissue. As such, it is 
difficult to visualize and correct for any tumour motion and/or regression between 
treatment fractions. This lack of image differentiation can ultimately cause loss of tumour 
control during treatment and increased normal tissue irradiation. The use of kV CBCT 
provides better soft tissue contrast than MV based photon imaging modalities. The kV 
CBCT also allows direct comparison with the planning CT, making treatment correction 
for tumour motion control easier [29].  
The addition of the kV CBCT modality into radiotherapy increases treatment precision. 
However, it increases the patient dose, and any additional dose is not displayed as part of 
the planned dose. Estimating the cone beam CT dose separately can be used to evaluate 
the effect of the CBCT dose on the planned dose. In most of the planning systems the 
effect of the CBCT dose (usually in the range of 1 mGy for head and neck and 25 mGy 
for chest and pelvis protocols [3]) is neglected as it is assumed to be very small in 
comparison with the dose associated with MV therapy (the typical dose for a solid 
epithelial tumour ranges from 40 to 70 Gy, while lymphomas are treated with 20 to 40 Gy 
[30]. However, it is important that the CBCT doses are determined accurately to avoid 
these patient doses exceeding organ threshold levels[31]. This project aims to determine 
the patient doses from CBCT during radiotherapy procedures, through measurement and 
modelling, to make sure that the CBCT doses are not pushing the radiotherapy doses over 
any organ related threshold levels. 
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2.1.6 Challenges associated with using CBCT 
Though CBCT supports and helps the overall patient treatment procedure by increasing 
the accuracy of treatment delivery, the amount of radiation dose received by the patient 
during this process is not being included or accounted for in the treatment planning 
process. The amount of extra dose from CBCT during radiotherapy procedures should be 
accounted for in the total dose calculations, especially around critical organs/structures. 
Even though the dose received by CBCT procedures is typically small it may push the 
critical organ dose limits over its threshold levels. Thus, the critical organs may have the 
radiation induced adverse effects in the future. To avoid such situations, and to ascertain 
the treatment scenarios where critical organ threshold doses are at risk of being reached, 
it is worthwhile to systematically measure the CBCT dose and investigate if the CBCT 
doses should be included in the total dose calculations and treatment planning process.  
 
For the accurate inclusion of CBCT doses into treatment doses the following are the 3 
mandatory steps that need to be fulfilled in the future. 
1) Accurate measurement of machine specific CBCT doses 
2) Construction of a protocol to incorporate the CBCT dose into the treatment 
planning system(TPS) 
3) Validation and monitoring of the CBCT dose incorporated into the TPS. 
 
There are many ongoing research projects on this topic, but it is difficult to generalize the 
dose measurement. This is mainly due the fact that the results might differ between 
manufacturers/models or even between two CBCT systems of the same model. Dose 
calculation methods are therefore not easily generalised, so a calculation algorithm may 
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need to be developed and specifically configured to give the correct results for a particular 
instance of a CBCT system.  
  
 Methodologies for Patient dose determination 
2.2.1 Clinical determination of CBCT doses 
The first attempt made in the clinical determination of CBCT doses was the attempt in 
2006 from Islam MK et al[2]. In 2007 the American Association of Physicists in Medicine 
(AAPM) task group 75 explicitly mentioned the need for imaging dose management. 
They stated that “Exposure to ionizing radiation presents two potential health hazards—
the risk of deterministic injury such as skin burns and cataracts and the probabilistic 
(stochastic) risk of inducing cancer or genetic defects. The danger of deterministic injury 
from prolonged fluoroscopy has been graphically demonstrated by several instances of 
severe burns following poorly monitored image-guided surgical interventions[32]”. It is 
also mentioned that the demand for high contrast, low noise, images continues to push 
the exposure levels up. Therefore, it is good to have doses optimized, keeping in mind 
that any increases in the expected dose always needs to be justified[32]. 
 
In 2013 JR Sykes et al [33] published a paper on current methods for dose measurement 
and calculation including measurements in cylindrical phantoms. The method is based on 
the use of point dosimeters in anthropomorphic phantoms, calculation of the dose using 
mathematical phantoms and calculation of individualised patient dose using Monte Carlo 
and modelling. Sykes et al [33] pointed out the importance of understanding the dose 
involved with CBCT imaging, exposure to aid in the reporting, optimisation and 
justification of each exposure. 
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Similar work was performed by Hu et al. [34] in 2014 for the measurement of the 
radiotherapy CBCT dose in a phantom using different methods.  This work particularly 
focussed on phantom dosimetry. Hu et al. [34] pointed out that phantom dosimetry is 
usually limited to scanning technique optimisation and comparisons between similar 
imaging devices. 
 
In 2015 Aleai P et al. [35] reviewed papers published on methods to calculate the imaging 
dose, including the use of Monte Carlo (MC) and treatment planning systems (TPS). This 
review emphasises that there is increasing awareness and strong interest in the evaluation 
of the concomitant dose from CBCT. Currently image guidance is becoming a very 
important part of the radiotherapy treatment of each patient. Treatment adaptation, based 
on dose re-calculation from the actual patient treatment position, is becoming increasingly 
possible. It is very important that we implement the tools needed to control and manage 
the potentially detrimental effects of any additional dose from incorporating on-board 
imaging devices and the associated procedures in optimising the patient treatment 
process.  
 
Since the publication of this task group report, there have been many attempts made to 
evaluate the CBCT doses in radiotherapy. These attempts can broadly be classified into 
three categories of papers that are focussed on research into:  
1) Measurement of the dose in anthropomorphic phantoms  
2) Measurement of patient skin dose and  
3) Dose calculation in mathematical model or patient geometries 
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 Measurement of dose in anthropomorphic phantoms   
Machine and phantom based studies are commonly performed on a Linear accelerator to 
obtain dosimetric evaluation of the dose. In most of these studies they have used TLD 
loaded phantoms to evaluate the doses. This category can be further divided into ElektaTM 
based and VarianTM based studies. 
 
2.2.1.1.1 ElektaTM Based CBCT studies 
All these studies were performed on either ElektaTM linear accelerators or ElektaTM 
LINAC simulations. The first of this class was performed by Islam MK et al. in 2006[2]. 
In this study the dose at the centre, periphery and on the surface of a 30 cm and 16 cm 
diameter cylindrical shaped water phantom were measured with an ion chamber and also 
metal–oxide–semiconductor field-effect transistor (MOSFET) detectors. The 
characteristics of this study were that a) all measurements were performed in air and at 
various depths of water using a 0.6cc farmer chamber b) The surface dose measurements 
for patients and phantoms were performed using a MOSFET dosimeter c) This study 
compared water phantom dose and patient skin dose with a bench top system they had 
made. This study concluded with the underlining statement of principle of radiation that, 
“A reduction in kVp and Field of view (FOV) can reduce patient dose”. 
 
Immediately after Islam et al. in 2007, Amer  et al. [36] performed a similar study. They 
used TLD chips in Rando phantoms to obtain the doses. They used the cone beam dose 
index (CBDI) formalism to obtain a dose indicator, as well as the skin dose for 9 patients; 
and Rando phantom measurements were compared with a CT simulation software 
program called Impact DoseTM, that calculated the organ dose. 
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In 2008 Parks et al. [37] performed a study to compare the peripheral CBCT dose and out 
of field dose from intensity modulated radiotherapy (IMRT) treatment. It was a study 
designed to evaluate the dose outside the target area. For the measurements with CBCT, 
TLD chips were used and for the evaluation of IMRT peripheral dose MOSFET detectors 
were selected. The aim of this study was to identify the risk of secondary malignancies 
associated with the peripheral dose. No organ dose evaluations were performed in this 
study. 
 
In 2013 Daniel Scundura and Catherine E Lawford[38] performed a study to evaluate the 
feasibility of different CBCT dosimetric tools. They concluded that the dose length 
product (DLPCBCT) dosimetry is superior to DLI dosimetry. A detailed explanation of 
DLP dosimetry can be found in Appendix 2 of this thesis. 
 
The latest study in this category is the evaluation of organ doses by Rampado et al[39] in 
2016. They evaluated and compared organ doses using Rando phantom and a virtual 
simulation CT software named PCXMCTM [40] (STUK, Helsinki, Finland). Additionally, 
they evaluated dose variability with respect to patient size and gender along with various 
dose indicators and cumulative dose. 
2.2.1.1.2 VarianTM Based CBCT studies 
In these studies, the most common CBCT system used was the VarianTM on board imager 
(OBI). The first of this kind was performed by Ning Wen et al[41] in 2006. In their study, 
for prostate cases they evaluated skin doses from 7 patients and compared it with the dose 
obtained from TLD chips placed on the IMRT QA (Rando) phantom. 
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In 2007 William Y song et al[42] performed a comparison study between VarianTM  based 
systems and ElektaTM based systems. They used acrylic phantoms to measure the CBCT 
doses during each protocol by considering CTDI as dose indicator. 
 
A similar study was performed by Sangroh Kim et al[43] in 2008, which differed from 
the previous study only in the phantoms that were used. They used CT phantoms (16 cm 
diameter for head phantom and 32 cm diameter for the body phantom), which is slightly 
different in size in comparison with acrylic phantoms (with diameters of 18 cm (head 
phantom) and 30 cm (body phantom)) used in the previous study. They also evaluated the 
dose due to the Multi Detector CT (MDCT). 
 
Monica W K Kan, et al.[44] evaluated the radiation dose from CBCT for IGRT in 2008. 
They calculated the effective dose to the body and absorbed doses to 26 organs. These 
measurements were done for two different technical settings named standard mode and 
low dose mode. They calculated the doses for a fan beam CT as well. All these 
measurements were performed on a female anthropomorphic phantom using TLDs. 
 
All the above studies were performed using VarianTM OBI version 1.3 equipment. This 
device uses high values for exposure parameters in its protocols. This increases the dose 
to the patient. Based on the research, VarianTM has developed since an improved version 
of OBI, Version 1.4 in 2008, which promised to reduce the imaging dose. 
 
In 2010 Asa Palm et al[45] carried out a study to identify the effectiveness of OBI V1.4. 
They calculated the patient dose for both OBI versions 1.3 and 1.4. For default imaging 
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modes, they found that the dose received for V1.4 were lower than the dose obtained in 
V1.3. 
 
In 2012 Alvarado et al[46] carried out a study to evaluate the radiation dose from CBCT 
for breast radiotherapy alone. They also evaluated the doses for lung, heart, and breast 
using XRQA2 radio chromic film and with PCXMCTM software. 
 Patient skin dose-based attempts 
It is difficult to measure the real-time organ doses on a real patient. This is limited because 
there are few natural holes in the human body that can be used to reach the critical organs. 
As a result, surgical incisions would be necessary if we needed to place measuring devices 
inside a human body. Thus, real-time organ dose measurements within the human body 
are limited to the skin dose in most cases.  
 
There are a few groups that have performed some systematic approaches to study and 
evaluate the cone beam CT dose to the skin. In 2006 Ning Wen et al[41] evaluated the 
skin dose for 7 patients undergoing radiotherapy treatment with the VarianTM  OBI 
equipment. Similarly, in 2007 Amer et al[36] also evaluated skin doses of 9 patients under 
an ElektaTM XVI treatment conditions.  
  
 Dose calculation in mathematical model or patient geometries   
Most of the studies of this type are being performed on a virtually simulated system. With 
the help of Monte Carlo codes either an ElektaTM or VarianTM based LINAC treatment 
situations are simulated. From this simulation the CBCT doses are estimated. 
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Most of these types of studies were performed by a physicist called George Ding and his 
groups. In 2007[47] they have used the Monte Carlo code BEAMnrc/ DOSXYZnrc 
(DOSXYZnrc is an EGSnrc-based Monte Carlo simulation code for calculating dose 
distributions in a rectilinear voxel phantom and is based directly on the DOSXYZ code 
developed for the EGS4 code. DOSXYZnrc is part of the OMEGABEAM system of 
codes developed at the National Research Council of Canada (NRC) for the dose 
calculation in a VarianTM based system. They have verified the reproducibility and 
accuracy of the code generated beam profiles and depth dose curves with water phantom 
measurements and found that they were within 3%. Likewise, they compared Monte 
Carlo based dose profiles with CBCT treated patient dose distributions. They calculated 
the additional dose to the organs which is not predicted by the TPS. They also developed 
a correction based algorithm in 2008 [48] for a dose calculation named the medium-
dependent-correction (MDC) algorithm, intended for an accurate patient dose calculation 
resulting from kilo-voltage (kV) X-rays. This algorithm is more accurate in calculating 
the CBCT dose in bone.  
 
In 2009 Ding et al. [49] modelled a kV CBCT beam from a VarianTM  OBI in a Pinnacle 
treatment planning system. They used this modelled system to calculate the dose to a 
phantom in the pelvic region and compared it with TLD measurements. The agreement 
between the two was within 5%. 
 
In the same year Ding et al. [50, 51] have used the above mentioned modelled system to 
develop “The Vanderbilt-Monte-Carlo-Beam-Calibration (VMCBC; Vanderbilt 
University, Nashville, TN)”, which is used to calculate the dose on an image to identify 
the dose due the KV CBCT system. 
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In the same year Spezi et al[52] also performed a Monte Carlo simulation for calculating 
the patient dose while using kV CBCT with a Monte Carlo code named BEAMPP. They 
simulated the ElektaTM Synergy LINAC and bow-tie filter. They have recommended that 
full three-dimensional dose calculation is necessary when adapting CBCT patient dose 
into any adaptive planning strategy. 
 
In 2013 again Ding et al[53] retrospectively calculated the imaging dose due to kV CBCT 
in radiotherapy procedures for 30 patients at different treatment locations. They used 
BEAMnrc code for beam modelling and DOSXYZnrc code for dose calculations. Their 
work showed that organ exposures can be further reduced to 15-70% of their original 
values with the use of a full-fan, bow-tie filter for kV radiographs. In contrast, organ doses 
increase by a factor of ∼2-4 if bow-tie filters are not used during kV-CBCT acquisitions.  
 
Similarly, in the same year David Montanari et al[54]  used a Graphical processing unit 
(GPU) based Monte Carlo simulation for CBCT dose evaluation in IGRT. They used a 
Monte Carlo dose calculation package named gCTD for the VarianTM OBI system to test 
the accuracy of the calculation and quantitative evaluation of the CBCT dose from the 
OBI System. Their comparisons with phantom measurements showed that the maximum 
dose is higher than mean dose by a factor of 1 to 3 depending on the organ and a high 
computational efficiency is predicted for the Monte Carlo (MC) code. 
 
2.2.2 Use of TLDs in CBCT Radiotherapy 
 Thermoluminescence was first described by British scientist Robert Boyle in the 17th 
century[55]. But the last 50 years has seen a dramatic increase in its clinical use, 
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especially in radiotherapy dosimetry. It is considered  one of the most versatile techniques 
in the field of radiation dosimetry measurements. TLDs have become popular in this field 
due to their high sensitivity, miniature size, tissue equivalence, high stability to 
environmental conditions, low TL fading, reusability, linear dose response and sufficient 
precision and accuracy[56]. TLDs can measure doses from the micro-Gy up to the 1 kilo-
Gy within the 5% threshold limit. 
 
The application of TLDs in medicine for clinical absorbed dose estimation has been 
carried out successfully for many years since the first proposal made by Daniels in 
1954[57]. Since then TLDs have become an integral part in most of the medical physics 
departments across the world. TLD dosimeters are small, nearly tissue-equivalent and 
sensitive. They can be conveniently attached to, or internally located in, the patient and 
are easily retrievable. Detailed explanation of the working of TLDs is given by 
Mandoswski in his paper “The theory of thermoluminescence with an arbitrary spatial 
distribution of traps” [58]. 
 
Most of the Cone beam CT dose measurements are performed by taking TLD 
measurements as base study. Out of the above mentioned studies the studies performed 
by Amer et al[36] in 2006, Wen et al[41] in 2006, Kan et al[44] in 2008, Kim et al[43] 
2008, Perks et al[37] in 2009, Sawyer et al[59] in 2009, Palm et al[45] in 2010, Wood et 
al[3] in 2015 and Rampado et al[39] in 2016 also performed numerous studies using 
TLDs. 
2.2.3 PCXMCTM as a Cone Beam CT simulation software 
It is important to regularly study CBCT procedures to improve the techniques used and 
expected outcomes. Obtaining real patients for these studies is not practically possible on 
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all occasions. To overcome this limitation various simulation software packages have 
been developed over the years. In this section (2.2.3) the suitability of PCXMCTM [60] 
for the current study is discussed in detail along with its important features, benefits and 
limitations. 
 Selection of appropriate software for CBCT simulation 
Over the years, different software-based approaches have been developed and utilized for 
the simulation of CBCT. The first type in this category is the writing of code based on the 
individual study needs. The second approach is to adapt already developed codes and 
modify according to the study needs. Both of these approaches require appropriate 
specialist programming skills, time, budget and patience.   The third approach is to use a 
commercially developed code allowing rapid implementation for short projects with 
limited budgets. 
 
This project was limited by many constraints such as time, budgetary concerns, and access 
to the needed technical infrastructure and associated skilled operators. Developing a new 
code, or adapting other codes was outside the scope of the present project. After careful 
consideration of the restrictions imposed by this project, the use of commercially 
available codes was found to be the best option.  
A comparison of the commercially available simulation software, such as Impact DoseTM, 
CT ExpoTM, and PCXMCTM, yielded PCXMCTM as the best choice. The features like 
rotational mode, variability filters make PCXMCTM optimal for the CBCT simulations in 
this project, while CT based software was restricted by the need for the 360-degree 
rotation. 
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 General description 
PCXMCTM is a commercial software package that runs on a PC and is commonly used 
for planar diagnostic radiology dosimetry. The program is Monte Carlo based and 
calculates organ doses during radiological examinations. This program utilizes tissue 
weighting factors from ICRP 103 [60] published in 2007 and its older version ICRP 60 
[61] published in 1991 to calculate effective doses. This program allows the selection of 
patient sizes varying from paediatric to adult with ages ranging from 0, 1, 5, 10, 15 and 
adult. Further, if needed, it can manually simulate the size and weight of choice. Also, it 
can perform calculations with or without arms. It is developed by STUK (Radiation and 
nuclear safety authority in Finland). The anatomical data used in this Monte Carlo code 
is based on the mathematical hermaphrodite models  developed and published in 1989 by 
Cristy and Eckerman [62]. 
 
 Organ dose 
All organ doses calculated in this software are based on the Incident Air Kerma (IAK). 
IAK represents the air Kerma at the point where the central axis of the X-ray beam enters 
the patient without the application of back scatter. In PCXMC the air Kerma term is called 
EAK (entrance air Kerma) however this is in effect the same quality as IAK. It is 
calculated free in air without backscatter in units of mGy[63]. Input data can also be 
supplied in terms of entrance exposure (mR, free in air without back scatter) or air Kerma 
area product or dose area product (mGy cm2) or exposure area product (R cm2). In the 
absence of radiation measurements, the program is also able to estimate the incident air 
Kerma from the X-ray tube input current time product. 
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The dose calculation in PCXMCTM utilises a Monte Carlo (MC) method. The MC method 
is based on the stochastic mathematical simulation of the interactions between photons 
and matter. In this model photons are emitted from an X-ray source into a solid angle 
specified by focal distance and X-ray field dimensions.  The photons then interact within 
the defined phantom depending on the energies and physical probability distributions of 
the physical process that may be undergone. At each interaction point the energy 
deposition to the organ at that position is calculated and stored for dose calculation. In the 
PCXMCTM software, it calculates the energy deposited for the photoelectric interaction, 
Coherent (Rayleigh) scattering or incoherent (Compton) scattering. The reason for this 
limitation (i.e. pair production processes ignored) is implicit, since the software’s 
maximum photon energy is limited to 150 keV. 
 
The chain of interactions for a single photon is called the history of an individual photon. 
For a single photon, a large number of history events is generated to estimate the mean 
energy deposited in various organs of the phantom, which are then used for calculating 
the dose deposited in those organs. 
 
This software also can be used in calculating the risk of exposure induced cancer, based 
on the BEIR VII committee report published in 2006 [64].  
  
 
 Studies based on PCXMCTM  
 Early attempts found in the literature that make use of this software in the dose 
calculation for CT was by Khelassi-Toutaoui et al. [65] in 2008. They measured the 
entrance dose and organ dose using a Rando phantom using TLD dosimeters. The same 
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situation was then simulated using the PCXMCTM software and another Monte Carlo 
radiation transport code named PREPARE. They found that their experimental values 
correlated (within 28%) with PCXMCTM software for almost 60% of the samples. 
 
Similar work was undertaken for the breast region by Alvarado et al. [46] in 2013 using 
VarianTM equipment, Wood et al. [3] in 2015 using VarianTM  equipment measured doses 
in the pelvis, while Rampado et al. [39], in 2016 used ElektaTM equipment to evaluate 
organ doses specifically due to cone beam CT during head and neck, chest and pelvis 
radiotherapy procedures. Both groups used the Rando phantom with TLD dosimeters as 
their base study and compared the results with the PCXMCTM software calculated organ 
doses. All three use different approaches to filtration. Alvarado et al. [46] used a flat filter  
without considering the bow-tie filter. Wood et al. [3] and Rampado et al. [39] used 
multiple partition simulations to more accurately depict the shaped filter. 
 
Wood et al. [3] used a set of 28 radiation fields, covering eight projection angles at 45◦ 
from anteroposterior (AP) projection for the modelling of the rotational exposure. To 
compensate the thickness of the half-bowtie filter, they split the asymmetric field into 
four smaller regions and each region was modelled independently with different x-ray 
beam qualities. Rampado et al. [34] however measured the beam intensity across the 
shaping filter and utilized a two-partition approximation for the simulation with the use 
of projection data at every 5 degrees. The simulations of Alvarado et al. [46], Wood et al. 
[3] and Rampado et al. [39] were all constrained by the use of symmetric collimation by 
PCXMC, whereas Radiotherapy CBCT units employ asymmetric collimation.. 
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  Benefits and Limitations of PCXMCTM  
In regard to working with PCXMCTM, the following Benefits and Limitations of 
PCXMCTM  are emerged as follows [64]: 
Benefits 
 
1) The phantom sizes can be varied to demonstrate the patient size and age. 
2) This software can be used for CT simulation by manual means 
3) It can be used for CT simulation automatically 
4) Is not restricted to 360o rotation – unlike CT dose programs such as ImPACT, 
CTexpo etc. 
5) PCXMCTM allows a free adjustment of the X-ray beam projection and other 
examination conditions of radiography and fluoroscopy. 
6) Every measurement performed by this software is based on the reference point 
7) A field size calculator determines the field size at the reference point 
8) If input dose is specified in terms of dose area product (DAP), exposure area 
product, or current time product (mAs) the data is not distance dependant. 
Limitations 
 
1) PCXMCTM assumes a flat filter in the radiation beam. 
2) Bow-tie filters cannot be easily simulated. 
3) The scanning actions of some scanners may be difficult to simulate. 
4) The PCXMCTM software assumes symmetric collimation. 
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2.2.4 Commonly used CBCT protocols in Radiotherapy 
In TCH all the VarianTM based Radiotherapy Linear accelerators are equipped with a 
Kilo-Voltage Cone Beam CT on board imager (OBI) for patient verification and 
reproducibility of treatment. Depending on the tumour site under irradiation, the cone 
beam CT is performed on the patient under various protocols outlined by the 
manufacturer, VarianTM.  Under the VarianTM outlined system, there are basically 7 
protocols. Each of these protocols is descriptively explained in table 1. As seen in Table 
1 all protocols rotate through 200 degrees either beginning at 340o and finishing at 180o 
or starting at 180o and finishing at 340o depending on the gantry position at the time of 
acquisition. 
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Table 1 Different CBCT Protocols and its acquisition modes* 
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X-ray Voltage (kVp) 100 100 100 125 125 125 110 
X-ray current (mA) per projection 20 10 80 80 80 80 20 
X-ray millisecond (ms) per projection 20 20 25 13 25 25 20 
Number of projections 360 360 360 655 360 360 655 
Exposure (mAs) 145 72 720 680 720 720 262 
 
Gantry Rotation 
(degrees) 
200 200 200 360 200 200 360 
CTDIw,norm (mGy/100mAs) 2.7 2.7 2.7 2.6 2.0 3.4 1.8 
CTDIw   (mGy) 3.9 2.0 19.4 17.7 14.4 24.5 4.7 
Bow-Tie Full fan Full fan Full fan Half Fan Full fan Half Fan Half Fan 
Default Pixel Matrix 384×384 384×384 384×384 384×384 384×384 384×384 384×384 
Slice thickness (mm) 2.5 2.5 2.5 2.5 2.5 2.5 2.5 
Reconstruction filter sharp standard Sharp standard Standard standard Standard 
Ring suppression algorithm Medium Medium Medium Medium Medium Medium Medium 
** Note –mode not typically calibrated 
VarianTM medical Systems © 2014 
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In TCH these protocols are followed as per vendor recommendations. No 
corrections on the machine parameters based on patient parameters such as 
gender, age, height, weight etc. are performed. The frequency of performing 
CBCT for each treatment site throughout the course of treatment is outlined in 
table 2 
Table 2 Different Radiotherapy treatment sites and its guidelines followed in TCH for 
imaging during the treatment 
Sites Imaging Frequency 
Radical Brain Daily CBCT 
Radical H& N CBCT Weekly 
Radical Pelvis  CBCT on Fraction 1,2 
& 3 then Weekly Radical chest 
Radical Abdomen and other 
radical sites 
Daily CBCT 
Low dose palliative Weekly 
Breast(Tangents) Fraction 2, 3 & 4 then 
weekly  Breast (SCF+/- P.Ax) 
IMRT Prostate (IF intact 
Prostate) 
Daily CBCT soft tissue 
match 
Other IMRT Sites Daily CBCT for the first 
week, then weekly basis 
  
The total dose delivered to the cancer target in external radiation therapy is 
usually divided into smaller dose portions called fractions. Most patients get 
radiation treatments daily, 5 days a week (Monday through Friday) for 5 to 8 
 40 | P a g e  
 
weeks. Weekend rest breaks allow time for normal cells to recover. The total 
dose of radiation and the number of treatments is based on: 
• The size and location of the cancer 
• The type of cancer 
• The reason for the treatment (treatment intent) 
• Patient’s general health 
• Any other treatment that the patient is receiving 
Other radiation schedules might be used in certain cases. For instance, radiation 
therapy might last only a few weeks (or less) when it’s used to relieve symptoms, 
because the overall dose of radiation is usually lower than for a full treatment. 
In some cases, radiation might be given as 2 or more treatments each day. It 
might also be given as split-course therapy, which allows for several weeks of 
no treatment in the middle of the full treatment schedule so the body can recover 
while the cancer shrinks. The radiation oncologist will decide the best plan after 
consulting with the patient. 
 
2.2.5 Biological Effects of radiation  
The body can repair damage from radiation, chemicals and other hazards. 
However, there is no doubt uncontrolled exposure can cause detriment to the 
human body sooner or later. For low levels of exposure, the biological impacts 
and effects are either so small they may not be detected, or the probability of a 
harmful outcome is insignificant. In the case of radiation, living cells exposed to 
radiation can: (1) repair themselves, leaving no damage; (2) die and be replaced, 
much like millions of body cells do every day; or (3) incorrectly repair 
themselves, resulting in a biophysical change. Depending on the nature of the 
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effects, the biological effects of radiation can broadly be classified into two 
categories [66] 
1) Stochastic effects 
2) Deterministic effects 
 Stochastic effects of radiation 
This type of radiation damage is related to low-level, long term exposure to 
radiation. The basic properties of stochastic radiation related impacts are 
characterised by: 
• The probability of the effect occurring depends on the absorbed 
dose 
• The severity of the effect is independent of the absorbed dose 
• There is no dose threshold 
• This means that if you are exposed to large doses it makes the 
effect more likely to occur but does not increase the severity of 
the effect. 
• Examples of effects due to stochastic radiation damage include:  
• radiation induced cancer, leukaemia, genetic effects 
 
 Deterministic (or non-stochastic) effects of radiation 
This type of radiation damage is related to high dose, short period exposure. The 
basic properties of deterministic radiation are: 
• The severity of the effect depends on absorbed dose 
• There is a threshold dose below which effects do not occur 
• Worsening of the effect as dose increases over the threshold 
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• Always occurring once, the threshold dose is reached 
• Different effects, tissues and people have different threshold 
doses for deterministic effects 
The threshold for an effect to occur varies from a single dose of 0.5 Gy for bone 
marrow damage to between 5 and 6 Gy for permanent infertility[67] due to 
radiation damage of the ovaries or testicles. A single dose of 1 Gy is likely to 
make the lens of the eye turn milky while 5 Gy will cause a cataract. Example 
of effects due to deterministic radiation damage include cataracts, infertility, 
burns, radiation sickness etc. 
 
2.2.6 The Organs at risk (OAR) involved in different CBCT 
protocols 
Organs at risk are organs which might be damaged during exposure to a toxin or 
to some form of therapy. Organ at Risk (OAR) most frequently refers to healthy 
organs located in the radiation field during radiation therapy[68]. 
 
Under each treatment site there is a unique set of organs that needs to be carefully 
considered before the execution of a radiotherapy treatment plan. This is to avoid 
further complications in the future from damage to these associated organs.  A 
section of the major treatment sites and their specific associated set of organs are 
mentioned in table 3. 
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Table 3 Different Treatment sites and their Specific sets of associated organs 
Site Head& Neck area Abdomen Pelvis 
Organs Cochlea L*+R** Kidney L*+R** Femur _L* 
Parotid L+R** Liver Femur _R** 
Larynx CaudaEquina Rectum 
Oral Cavity Pancreas Bladder 
Temporal Lobe L*+R** Spleen Penis 
Mandible  Stomach Testis  
Lung L*+R** Thoracic and 
Lumbar vertebrae 
Prostate 
Spinal Cord  Urethra 
Brain stem  Uterus 
Eye Lens L*+R**   
Optic Chiasm    
Pituitary   
L* – left and R**- right 
 Critical organ dose limits[69], [67] 
 To avoid the future complications, a maximum acceptable organ dose for each 
organ is defined based on research and previous treatment records. The currently 
accepted threshold values for some of these organs are tabulated in table 4. 
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Table 4 Table showing different organ threshold doses 
Organ Maximum acceptable dose (Gy) 
Brain 60 
Contra lateral temporal Lobe 25 
Brain stem 54 
Optic Nerve/ Optic Chiasm 50 
Eye Lens  2 
Eye Retina 45 
Inner ear Max < 60 Gy, Mean <35 Gy 
Middle / External ear 55  
Parotid  Mean < 20 Gy for single Parotid 
Mean <25 Gy Both parotids 
Larynx Mean 45Gy 
Max 66Gy 
Brachial plexus 55 
Spinal Cord 45 
Cauda Equina 55 
Lung (2Gy/F) <15 Gy 
Stomach <45 Gy 
Femoral head V52Gy<10% ** 
Bladder V80Gy<15% ** 
V75Gy<25% 
V70Gy<35% 
V65Gy<50 % 
Penile bulb <52Gy 
Uterus 14-30 Gy[69] 
** V52Gy<10% - Volume of (organ) receiving 52Gy or more should be 
less than 10% 
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Chapter 3 
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3 Methodology 
Two dose methods are described in this section as each has different advantages.  
An advantage of computer simulation is that the organ dose estimations can be 
varied depending on the size of the phantom used for the simulation. On the other 
hand, TLD measurement is an established methodology used frequently in the 
literature. However, this method is restricted to a set size of patient. A detailed 
explanation of methodologies of dose simulation and TLD measurement are 
explained in the following sections including an estimation of associated errors. 
 
 Dose simulation  
The most appropriate software to simulate cone beam CT applications in 
radiotherapy for this study, as discussed in section 2.2.3, was found to be 
PCXMCTM. This software was used to determine organ doses through the 
simulation of CBCT treatment protocol with the feature of being able to vary the 
patient size. The equipment used, apart from the PCXMCTM software, was 
Unfors XiTM detectors, VarianTM trilogy Clinac Linac and VarianTM OBI setup 
with Bow tie filter. It is important to understand that PCXMCTM rotation 2.0 
software does not simulate exactly every scanner, as some scanning actions may 
be difficult to simulate. However, this point is often neglected to allow 
simulations to occur. 
The software used was PCXMCTM Rotation2.0 run on a Microsoft ExcelTM 
platform (see appendix 6 for more details). The rotational software additionally 
required the use of supplied Excel sheet that was operated by specific macros. 
These supplied macros had to be rewritten due to incorrect references to 
directories. As seen in 2.2.3.4 care has to be taken when using PCXMCTM 
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generally and particularly in rotation mode with special emphasis on (i) the 
Reference point air Kerma which needs to be measured for every simulation at 
the reference point of the actual CBCT unit, (ii) filter simulation, including the 
effects of varied filtration on x-ray output and beam quality (iii) the portioning 
of the simulation to simulate the shaped filter and (iv) the variation of phantom 
sizes. 
3.1.1 Reference Point Air Kerma Measurements 
Calculation of Reference Point Air Kerma  is one of the critical steps involved 
in the PCXMCTM simulation methodology. An ionization chamber (RaySafe 
XiTM CT detector) was used to measure the reference point dose air kerma for 
both kV settings, each with the applicable filter in place. The ion chamber and 
electronics are combined into one unit making it possible to measure both 
temperature and pressure to actively compensate for this dependency. The 
temperature and pressure are measured inside the ion chamber giving very 
precise compensations both with and without a CT phantom. With no baseline 
drift, this carbon fiber ion chamber is ready to use within one minute. For the 
RaySafe XiTM CT detector annual calibration is performed at RaysafeTM, Sweden 
and their calibration certificates are traceable to PTB and NIST. The 
experimental setup is shown in figure 5. 
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Figure 5 Experimental setup used for measuring the reference air Kerma 
  
 
To perform reference point Air Kerma measurements a 10 cm pencil ionization 
chamber was set up at the isocentre of the Cone beam CT system. The chamber 
was fully irradiated along its axis, thus integrating the air kerma to give and 
average along this length. Once the setup was completed, the cone beam CT 
protocol for the head and pelvis were performed to measure the air kerma for a 
complete protocol. This measurement value was then divided by the number of 
dose simulation projections to determine the air kerma needed for the simulation 
software. 
The simulation software, PCXMCTM rotation, utilised a supplied ExcelTM 
sheet. A 3.0-degree increment of the projections was chosen for the simulation. 
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The number of simulation projections was determined by dividing the total scan 
angle by 3 degrees plus one. It was noted that for both the head and pelvis spot 
protocols that the CBCT system offsets two degrees, so for one side starting, it 
would start from 338 degrees instead 340 degrees and stops at 182 degrees 
instead of 180 degrees, giving a total of 204 degrees. This gives the total 
simulation projections as 69.    
3.1.2 Simulation of a Bow-Tie filter and subsequent application 
of PCXMC 
For the dose calculation , it is necessary to determine the appropriate HVL of the 
CBCT incident beam with the bow-tie filter attached. As the PCXMCTM rotation 
2.0 software doesn’t consider the bow tie filter geometry in the simulation, it is 
necessary to simulate the filter manually. Because of this, the experimental part 
of PCXMCTM methodology can be divided into three parts. 
1) Dose profile measurement 
2) HVL profile measurement 
3) Simulation of Bow-tie filter through partition simulation 
 
 Dose Profile Measurement 
The dose profile measurement was performed using an Unfors XiTM detector. 
During the measurement one detector is placed in the radiation field as a beam 
output monitor to evaluate any fluctuations in the radiation field. The 
measurement detector was moved across the radiation field with an increment of 
2 cm between measurements. These measurements for 100 kV beams and 125 
kV beams were given in Appendix 3.   
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Figure 6 Experimental setup for dose profile and HVL measurement 
 
The profile measurement results are found in Appendix 3 and these results are 
used in section 3.1.2.3 
 
 Half Value Layer (HVL) Measurement 
The intensity of the X-ray beams is reduced as the beam is attenuated through a 
shaped filter. The Half Value Layer (HVL) is used to measure the radiation 
quality and/or penetration potential of the beam and can be used to determine the 
filter thickness. It is defined as the amount of absorbing material that is needed 
to reduce the beam intensity to half of its original value. While normally it is 
measured under narrow beam geometry, the Raysafe Xi devise can measure the 
HVL directly in a broad beam. The result is traceably calibrated for 2 mm of 
aluminium.  
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The HVL of the beams for both Head and Pelvis protocols was measured at 
points along the isocentre of the CBCT unit to represent the curved portions of 
the bow-tie filter, spread across the bow-tie filter as shown in figure 2. From the 
previous output profile measurement (appendix 3), it was found that the beam 
profile was symmetric. 
Two Unfors Xi chambers were setup in the light field such that one chamber was 
the actual detector and the second one acted as monitor chamber. The results of 
this are seen in appendix 4 and used in section 3.1.2.3.  
 Simulation of Bow-tie filter through partition 
 
Since PCXMCTM software assumes only the flat filter geometry for simulations, 
it is necessary to simulate the bow-tie filter. This is done through the use of four 
simulation blocks or partitions for each protocol. Each of these blocks need to 
have the average air kerma weighting as a percent of the total air kerma at the 
reference point, the collimation width and the average total filtration. To achieve 
these parameters the following 5 steps were performed. 
i. Step 1 - determining the % air kerma for partitions 
A graph of normalized percentage reference air kerma was plotted and fitted with 
a polynomial fit equation of 6th degree for both 100 kV and 125 kV beams 
(figures 7 and 8 respectively). 
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Figure 7 Normalized beam profile for 100 kV X-ray beam 
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Figure 8 Normalized beam profile for 125 kV X-ray beam 
ii. Step 2 – investigation of the relationship between dose profile and 
HVL 
 
The relationship between the dose profile and the HVL was established 
as seen in Figures 9 and 10 where data from Appendix 3 and 4 has been plotted 
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for both 100 kV and 125 kV beams. Each figure also contain the fit equations 
that are used in later steps.   
 
 
Figure 9 HVL vs Percentage dose curve for 100 kV X-ray beam 
 
 
Figure 10 HVL vs Percentage dose curve for 125 kV X-ray beam 
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iii. Step 3 – conversion of HVL to total filtration 
The fitted equations describing the HVL as a function of distance from isocentre 
obtained for the 100 kV and the 125 kV beams (appendix 4) were used to 
generate tables in steps of a positional increment of 0.1 cm (appendix 5). It is 
necessary to convert the measured HVL values to total filtration. For this 
purpose, an online equivalent spectrum generator provided by SiemensTM 
located at the following web address was used “https://www.oem-xray-
components.siemens.com/x-ray-spectra-simulation”. The spectrum generator was 
used in an iterative process, using a tungsten target and accelerating voltage of 
100 kV and 125 kV, to give the values in tables 5 and 6. 
Table 5 Table of Percentage doses and its corresponding equivalent HVLs and distance from 
isocentre 
% Dose 
(%) 
100 kV - Head 
HVL 
Value 
(mm Al) 
Filter thickness 
(mm Al) 
Distance 
from 
isocentre 
(cm) 
83.00 4.99 3.50 2.6 
50.00 6.71 9.50 5.1 
24.00 8.39 15.70 7.2 
10.00 9.56 25.00 13.3 
 
Table 6 Table of Percentage doses and its corresponding equivalent HVLs and Distance from isocentre 
% Air 
kerma 
(%) 
125 kV - Pelvis 
HVL Value 
(mm Al) 
Filter 
thickness (mm 
Al) 
Distance 
from 
isocentre 
(cm) 
83.00 5.58 2.70 2.7 
50.00 7.31 6.65 5.33 
23.00 8.99 13.90 8.19 
10.00 10.17 23.10 16.12 
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iv. Step 4 – formation of partitions for simulation 
In order to best simulate the effect of the shaped filter, an arbitrary decision to 
make 4 partitions was made. Normalised dose profiles, from Figures 7 and 9 
were partitioned as seen in figures 11 and 12. 
 
 
Figure 11 Dose profile showing the four partitions with their percentage contributions on the left and 
the collimation width indicated on the horizontal lines in each partition for the Head protocol at 100 kV 
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Figure 12 Dose profile showing the four partitions with their percentage contributions on the 
left and the collimation width indicated on the horizontal lines in each partition for 
the pelvis spot protocol 
 
For an accurate simulation, the collimation widths at 83%, 50%, 23% and 10% 
of the dose profile were used being the halfway point between normalised doses 
of 100% & 66%, 66% & 33%, 33% & 10%, and 10% &0%. By using this 
approach, two equal triangles across the dose profile were created such that the 
one outside the dose profile curve and the other inside the dose profile curve are 
effectively equal.  
For each partition the total filtration and collimation widths were utilised in the 
simulation performed using the ExcelTM sheet of PCXMCTM software. 
v. Step 5 – Application of model to PCXMC 
Before running the scripts, it was necessary to input values for variables 
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projection angle increments, oblique angles if any otherwise zero, patient 
identification number, patient height, patient weight, patient age, X-ray tube 
voltage, filtration materials and thickness, focus to reference distance (FRD), X-
ray beam width at FRD, and x, y and z coordinate reference points. Also, there 
is a need to specify whether we need to include the arms in the phantom for the 
dose calculation. A screen shot of PCXMCTM software simulation is shown in 
figure 13. 
 
 
Figure 13 Screen shot of PCXMCTM software showing input parameters 
The incident air Kerma (IAK) per simulation projection value is input into the 
program. The process to determine this is described in section 3.1.1. The detailed 
explanation for running the macro script is provided in Appendix 6. For each 
section the PCXMC software is run for each projection angle. This process is 
automated giving an output into Excel format (see section 3.1 and appendix 6 
including notes on needed modifications made to software). This output give the 
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total dose for each organ, the relative error of measurement (see section 3.1.4) 
and the effective dose. 
 
The total dose weighting for each simulation component, corresponding to the 
simulation of the bow tie filter, needs to be assigned. This was determined by 
considering the difference between the dose percentages considered in step 2 
described above. As an example, the first simulated step profile at 3.5 mm Al 
equivalent HVL and a collimation width of 5.4 cm a weighting of 34% is 
determined. This was based on the calculation of the dose percentage between 
100% and 66% normalised dose. 
3.1.3 Effect of phantom size measurements 
An important aspect of using PCXMCTM for simulations was that the soft 
phantom size can be altered to simulate its effect on the organ dose calculation. 
To identify the impact of phantom size we have used two different virtual 
phantom sizes in the simulation. One was the actual Rando phantom size, with 
data supplied by the Rando phantom manufacturer (see appendix 7). The other 
was the standard Australian human data supplied by Australian Bureau of 
statistics website (See appendix 8). The comparison of these two data sets and 
the PCXMC default values are given in the table 7. This data was used in the 
PCXMC simulations. 
Table 7 Comparison data for standard Rando man and Standard Australian man  
Physical measurements Standard 
Australian man 
Standard 
Rando man 
Standard 
PCXMC 
Height (cm) 175.6 175 178.6 
Weight (kg) 85.9  73.5 73.2 
BMI (kg/M2)      27.86 24 23.04 
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3.1.4 Estimation of errors from use of PCXMC 
For each simulation, PXCMC calculates the statistical error for absorbed 
energies as one standard deviation in percentage each organ dose [70]. The 
quantity is controlled by (a) the fixed number of photons in the simulation, (b) 
attenuation within the phantom and (c) Poisson statistics, plus computation 
influences (numerical rounding and truncation errors). In order to determine the 
statistical error for each organ for the entire simulation, the associated errors for 
each projection need to be combined. This was done using quadrature 
summation. Detailed error calculation is given in appendix 15. 
 
It should be noted that the accuracy of both the dose estimate and its statistical 
error depend on the number of simulated interactions in the organ considered. 
The number of interactions may be low even for a large number of photon 
histories if the dose in the organ is low and/or the organ is small. It should also 
be noted that when the number of interactions is small, which is indicated by a 
high value of the statistical uncertainty (several tens of percentage points), the 
estimate has a skewed non-normal distribution and the actual statistical errors 
may be significantly larger than expected on the basis of the standard deviation. 
However, it should be understood that the statistical error is usually a small 
component of the total uncertainty determined as part of the final result. The 
differences between the phantom and the actual patient, and the differences 
between the simulated and true geometry will often dominate. 
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 TLD Measurements 
3.2.1 Introduction 
TLDs are widely used to determine patient doses in radiation diagnostics and 
external beam radiotherapy. The dose ranges of interest are approximately 0.1–
100 mGy for clinical X-ray diagnostics and 1–5 Gy for radiotherapy [71], [72]. 
TLDs possess advantageous characteristics that allow for easy use and 
reproducibility in both clinical and research settings, such as their small size, 
reusability and few correction factors to be applied [73], [74]. This popularity is 
due to its approximate tissue equivalence  low signal fading (5%–10% per year), 
wide linear response range (10μGy- 10Gy); and high sensitivity for very low 
dose measurements [75]. Due to their small size, TLDs are convenient for point 
dose measurements in phantoms as well as for in vivo dosimetry on patients 
during radiotherapy treatment [56]. 
A set of TLDs were used to measure the dose delivered to organs with two 
selected protocols. The first was the standard head protocol and the second was 
the Pelvis spot protocol. 
 
3.2.2 Equipment Used 
The CBCT unit was a VarianTM Trilogy Linear accelerator with OBI setup. TLD-
100H chips were used due to their flat sensitivity response at diagnostic radiation 
energies [76] These were placed in a Rando phantom and read out by a Harsaw 
TLD Reader Model 5500 and WinRemsTM software. For calibration of the TLD, 
two Unfors Xi detectors were used with a GE health care mobile X-ray unit 
(model AMX-4), VarianTM Trilogy Clinac Linear accelerator and OBI setup, 
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Rando phantom, Harsaw TLD Reader Model 5500 and WinRemsTM software, 
TLD-100 chips, and 3D slicer software. 
   
3.2.3 Procedure 
 Storage and identification 
 
As TLD chips are highly subject to physical damage they must be handled with 
great care. A holder (see Figure 14) was therefore constructed for safe storage of 
the chips. Another propose of the holder is to allow for efficient chip 
identification. The chips are identified using a coordination system: horizontal 
axis from 1 to 10 and vertical axis from a toe. This was vital for individual 
calibration and keeping track of the dosimetric and heating record of each 
individual chip. 
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Figure 14 Picture of Perspex TLD chip holder used in TCH for storage 
 Batch calibration 
The TLD chips were prepared through a batch calibration process to obtain the 
individual calibration factor to compensate for variations in the sensitivity of 
each chip. A chip with a calibration factor more than 1 standard deviation from 
the mean was rejected. The calibration process followed was to irradiate the 
chips with a uniform X-ray field so to determine any variation in TLD response. 
All 50 chips were irradiated inside the holder with an identical beam quality of 
80 kV, 2 mm Al added filtration and 40 mAs. After careful examination of the 
irradiation history, 50 TLD chips with the most consistent sensitivity were 
identified and used for the cone beam CT measurements.  
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 Dosimetric calibration 
A dosimetric calibration setup was determined for both 100 kV and 125 kV 
beams using a GE AMX4 mobile x-ray unit. In each case 3 beam energies were 
used to determine sensitivity variations over a range of effective beam energies 
that might be encountered due to the use of shaped filter1 or beam energy 
variations within the phantom2 [IAEA TRS457]. The reference dose was 
provided by an Unfors Xi dosimeter with current calibration traceable to the PTB 
standard laboratory. The calibration is in air kerma as consistent with IAEA 
recommendations [IAEA TRS 457]. Additionally, a monitor chamber was used 
to correct for any output variations between the detector and TLD exposures.  
For each measurement set, three different voltages used were calibrated to be 90 
kV, 100 kV, and 110 kV (see appendix 10). The detector or the TLD chips were 
kept at 100 cm from the source. The monitoring chamber was at 130 cm. The 
Field size at the detector level was 30 cm x 17 cm. For all three voltages, the 
mAs was kept constant (32 mAs). For each voltage, an additional 2 mm Al 
                                                 
1 The X-Ray beam after leaving the tube passes through filter material to remove low energy 
photons. Typically specially shaped filters are then applied near the collimator to compensate 
for attenuation difference in the patient’s head or body. In this case a bow-tie filter was used 
2 density differences due to the material of manufacture 
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filtration was added. The schematic representation of the experimental setup is 
explained in Figure 15.  
 
 
Figure 15 TLD calibration factor measurement setup for 100 kV X-ray beams 
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For each beam energy, the observed tube voltage value, tube output, dose read 
by both the standard detector and monitor were noted. This was repeated until 
constant values were obtained.  
 
The background corrected TLD readings were obtained using a Harsaw TLD 
Reader Model 5500 and WinRemsTM software. The calibration factor quoted is 
obtained from an average of the ratio of the dose detected by the detector 
chamber and the average charge detected by the TLD chips irradiated at each 
voltage. The TLD calibration form is attached as Appendix 11. For the Pelvic 
measurements, the calibration was performed in the similar fashion. The only 
difference to the 100 kV calibration was that, the CBCT unit was used to deliver 
the beam (see Appendix 11). Using the individual correction factors and 
calibration factors the dose at different organ sites were calculated. Data analysis 
was carried out using ExcelTM 2016 software. 
 
 Reading cycle 
After irradiation, the TLD chips were left in the normal room temperature for 24 
hrs before reading. For all reading, except the batch calibration reading, 
individual chip corrections were made as well as the reader calibration factors 
(RCF) as calculated using Harsaw TLD Reader Model 5500 and WinRemsTM 
software. 
The reading cycle for the TLDs used a lower temperature treatment kept constant 
at 145ºC for 10 seconds, with the higher temperature treatment kept at 260°C for 
10 seconds. The heating rate was kept at a rate of 10ºC/s. Screen shot of the 
temperature profile is attached Figure 16. 
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Figure 16 Time temperature profile used for reading the TLD chips 
 
 Placement of TLDs in Rando Phantom 
The Rando phantom was then used for the TLD measurements. In order to 
measure organ doses applicable to patients, it was decided that the organ 
boundaries in the phantom should correspond as best as possible to typical 
patients of the same size as the Rando phantom, rather than follow the soft 
phantom organ positions as defined by PCXMC. 
 
In order to identify the positions of relevant organs in the phantom, a CT of 
Rando Phantom was performed. The Digital Imaging and Communications in 
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Medicine (DICOM) images obtained of the phantom were carefully examined 
using software called “3D slicerTM” to obtain the positional description of the 
relevant organs. The delineation of Organs at Risk positions within the Rando 
Phantom was performed with the help of experienced radiographers. For this 
delineation, the phantom images were scrutinized thoroughly to identify the 
bony marks in the phantom. After identifying the anatomical landmarks, the 
organs at risk are drawn with the help of anatomically explained positions of the 
OAR. To confirm the positions, the phantom images are matched with actual 
human images of the head and pelvis with the help of experienced radiographers.  
 
In the case of mathematical models, the organs, can be defined by a Boolean 
operation. However, even with complicated and carefully designed Boolean 
operations, phantoms based on several surfaces are not anatomically accurate. 
The true shape of a human organs is more amorphous and cannot be described 
by a simple Boolean operation. Whereas the Rando Phantom consists of natural 
human skeleton enclosed in tissue-simulating plastic means it is closer to the 
human Anatomy. Therefore, segmenting Rando based on the mathematical 
model, creates more deviation from actual values. 
 
Used Anatomical landmarks for each OAR are explained as follows: 
Brain Stem: The cranial border of the brainstem was defined as the bottom 
section of the lateral ventricles, the caudal border as the tip of the dens of C2 
(cranial border of the spinal cord) [77].  
Parotid Gland: The parotid glands are the largest. They are situated in the 
lateral region of the neck, called the parotid region, or parotid space, under the 
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pinna and the external auditory meatus posteriorly to of the mandibular ramus 
and at the front of the sternocleidomastoid muscle. They are connected to the 
oral cavity through the Stensen’s duct, which terminates in the cheek, close to 
the superior molar [77, 78]. 
The land marks are Cranial- Inferior edge of external auditory canal, Caudal -
Inferior margin of mandibular branch and Lateral -Subcutaneous adipose tissue 
 
Spinal Cord: The cranial border was defined at the tip of the dens of C2 (the 
lower border of the brainstem), and the caudal border at the upper edge of T3. 
Here the full body phantom is not used therefore the caudal border was C5 [77]. 
 
Eye: The eyes were clearly visible and identifiable from the CT images 
Similarly, for the Pelvic region the following organs were considered. 
 
Uterus: The exact anatomical location of the uterus varies with the degree of 
distension of the bladder. In the normal adult uterus, it can be described as 
anteverted with respect to the vagina, and anteflexed with respect to the cervix: 
Anteverted: Rotated forward, towards the anterior surface of the body. 
Anteflexed: Flexed, towards the anterior surface of the body. 
Thus, the uterus normally lies immediately posterosuperior to the bladder, and 
anterior to the rectum[79]. 
 
Urinary Bladder: The empty bladder is completely contained in the small 
pelvis, behind the pubic symphysis, in front of the uterus in females and the 
rectum in males. The superior portion is hollow and covered by the peritoneum, 
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whereas the inferior portion, positioned on the posterior surface of the pubic 
symphysis, is convex[68]. 
 
Prostate: The prostate is a small muscular gland located inferior to the urinary 
bladder in the pelvic body cavity[80]. 
 
Femoral Head: The femoral head represents the proximal termination of the 
femur, forming by itself the thigh skeleton. It has a round shape and is set in the 
acetabulum, with which it articulates[68]. 
 
After drawing the OAR on the 3D slicer the position of the OARs from the 
border of the images were measured using the ruler. Then the position is 
transferred to the phantom. 
 
TLD chips were placed near the centre of identified organs. A more complete 
sampling could not be achieved due to the limited number of TLD chips 
available. Where possible the predrilled holes were used however, they did not 
always include the required positions according to the determined positions of 
the necessary critical organs in the head (see section 2.8.1). As a result, a number 
of holes were carefully drilled in the phantom (2.5 mm deep) wherever it was 
necessary. 
 
 For each site, 3 chips were selected and used to assist in estimating the error and 
to identify any non-performing chips. For the head related measurements, ten 
organ sites (three sites for spinal cord, three sites for brain, one site each for left 
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and right parotid glands as well as the left and right eye) were identified on the 
Rando phantom. The identified positions and allotted TLD chips are detailed in 
Table 8. At each site 3 TLD chips were inserted with careful attention to the 
numbering of the chips.  Additionally, 15 chips were kept aside for calibration 
(D1, D2, …. D10, E1, E2……E5)) and 5 chips for background determination 
(E6, E7, ….. , E10) measurements. The arrangement of the TLDs in the Rando 
Phantom and their irradiation setup are shown in Figure 16. Note TLDs used for 
the eye are placed on the surface, for ease of application, and not at 3 mm depth 
for eye lens or deeper for average eye dose. However it should be noted that CT 
dose distribution approaches uniformity through the head.  
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Figure 17 Figure showing TLD chips arranged in Rando head phantom. A , B Represents Rando 
phantom head slices loaded with TLD chips ; C represents Rando Head Phantom with fully loaded TLD 
Chips 
 
 
 
 
 
Table 8 TLD chip names and their subsequent arrangement of positional description in Head phantom 
 
TLD Arrangements 
  
Status Organ 
Site Name, slice 
number, position TLD Used 
Individual 
calibration 
factor 
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This was repeated for the pelvic region with 6 organ sites and 10 points across 
the bladder plane. The positional arrangement of TLD chips for the pelvic region 
are mentioned in Table 9. Arrangement TLDs in Rando Phantom and their 
irradiation setup are shown in Figure 17. 
Measurement 
Spinal cord 
A, (top) 
A1 0.98 
A2 1.15 
A3 0.99 
B (middle) 
A4 0.98 
A5 1.27 
A6 0.99 
C (bottom) 
A7 0.87 
A8 1.16 
A9 0.95 
Brain  
D (top) 
A10 1.08 
B1 1.12 
B2 1.15 
E (middle) 
B3 1.20 
B4 1.01 
B5 1.08 
F (bottom) 
B6 0.99 
B7 1.03 
B8 1.03 
Parotid gland 
G (left) 
B9 1.07 
B10 0.95 
C1 1.28 
H (right) 
C2 0.90 
C3 1.24 
C4 1.01 
Eye 
I (left) 
C5 1.16 
C6 0.88 
C7 1.16 
J (right) 
C8 1.06 
C9 1.10 
C10 0.96 
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Figure 18 Figure showing TLD chips arranged in Rando head phantom. A, B Represents Rando 
phantom pelvic  slices loaded with TLD chips; C represents Rando Phantom with fully loaded TLD Chips 
arranged in LINAC for pelvic irradiation 
 
 
Table 9 TLD chip names and their subsequent arrangement of positional description in pelvic region of 
Rando phantom 
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Status Organ TLD Used 
Individual calibration 
factor 
Measurement 
Uterus 
1A 0.94 
2A 1.03 
3A 1.05 
F. head Left 
4A 0.94 
5A 1.05 
6A 0.98 
F. head right 
7A 0.96 
8A 1.05 
9A 0.98 
prostate 
10A 0.99 
1B 1.06 
2B 0.94 
Bladder 
3B 0.98 
4B 0.96 
5B 1.07 
Bladder plane Left lateral 1 
6B 0.99 
7B 1.04 
8B 1.06 
Bladder plane Left lateral 2 
9B 1.03 
10B 0.99 
1C 0.97 
Bladder plane Left lateral 3 
2C 0.93 
3C 0.97 
4C 1.02 
Bladder plane Left lateral 4 
5C 1.01 
6C 0.95 
7C 1.06 
Bladder plane Left lateral 5 
8C 1.02 
9C 0.95 
10C 0.99 
Bladder plane right lateral 5 
1D 0.99 
2D 0.93 
3D 1.01 
Bladder plane right lateral 4 
4D 0.95 
5D 1.01 
6D 1.02 
Bladder plane right lateral 3 
7D 1.01 
8D 1.02 
9D 1.03 
Bladder plane right lateral 2 
10D 1 
1E 0.95 
2E 1.06 
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Bladder plane right lateral 1 
3E 0.93 
4E 1.08 
5E 0.92 
Skin front 
6E 0.93 
7E 0.93 
8E 0.92 
Background 
9E 0.93 
10E 0.92 
F1 0.92 
F2 0.93 
F3 1.08 
F4 1.07 
 
To check energy sensitivity of the TLDs the x-ray machine was set to give three 
beam energies corresponding to 90 kV, 100 kV and 110 kV (see appendix 10). 
The kV range chosen (90 to 110 kV) was to cover the possible energy range 
within the phantom for the OBI which was operated at 100 kV.2 The energy 
sensitivity range was identified as being within 5% for these energies and so the 
same sensitivity factor was used for all TLDs including the 125 kV beam.  
  
The phantom head was attached to the body to better simulate the scatter 
radiation from the body. The phantom was set on the treatment couch using the 
lasers. The CBCT protocol was then used with the standard head protocol from 
VarianTM (Table 1). The CBCT rotation was performed in the clockwise 
direction, starting from angles of 178° to 22°. The screen shots of the console 
before rotation and after rotation are attached as appendix 9. The detailed 
description of exposure parameters is mentioned in section 2.2.4. 
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4 Results 
 PCXMCTM 
The PCXMCTM software Simulation results were tabulated for each of the 
treatment protocols in the following sections. 
4.1.1 Reference point Air Kerma Measurements  
The reference point Air Kerma for head protocol and pelvis spot protocol were 
measured. Each protocol used 360 projections. The average dose per projection 
is tabulated in table 10 showing good reproducibility (COV <1%). The total dose 
is equal to the dose per projection times the number of projections. 
 
Table 10 The Reference air Kerma measurements for Head and Pelvis spot protocols 
Protocol kV Measurement (µGy) Total dose for the 
protocol (mGy) 1 2 3 Average 
Head 100 32.96 32.96 32.97 32.96 11.87 
Pelvis 125 209.1 209.1 209.1 209.1 75.28 
4.1.2 Simulation of Bow-Tie filter and subsequent Organ dose 
calculation 
The Bow-tie filter is simulated using a step approximation and organ doses at 
each step were calculated using the PCXMCTM rotation 2.0 ExcelTM sheet. The 
detailed calculation charts for rando man head given in table 11. The simulation 
was done using 100 kV beam with a reference dose per simulation projection of 
0.172 mGy (This is obtained from dividing the total reference point Air Kerma 
for the protocol by the number of simulation projections.). The associated 
statistical error from the Monte Carlo simulation program is also included. See 
appendix 14 for standard Australian man calculations and further discussion. 
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Table 11 Organ dose calculations for standard Rando man Head Protocol Using PCXMCTM simulation with 
combined statistical error 
Simulation 
Parameters 
 Partitions 1 2 3 4 Total 
% 
error 
HVL (mm Al) 3.8 8.92 19.1 23.1 N/A N/A 
Collimation Width 
(cm) 
5.2 10.2 14.4 26.6 N/A N/A 
% weighting for each 
step 
34 33 23 10 100 N/A 
Organ 
Dose 
(mGy) 
Parotid Gland 1.82 4.31 7.42 8.41 4.59 17.62 
spinal cord upper 4.31 7.52 9.31 9.84 7.08 9.55 
Spinal cord middle  0.02 0.05 0.08 0.09 0.05 68.35 
Spinal cord lower 0 0 0 0 0 N/A 
Skull 5.02 12.01 18.33 21.47 12.03 3.05 
Brain 2.31 5.46 8.01 8.82 5.31 4.37 
Oral Mucosa 1.15 3.18 5.41 6.56 3.34 23.26 
  
 
Similarly, for the pelvis the detailed calculation chart is given in table 12. The simulation 
was done using 125 kV beam with a reference dose per simulation projection of 1.091 
mGy. 
 
 
 
 
Table 12 Organ dose calculation for Rando man Pelvis Spot protocol using PCXMCTM simulation with combined 
statistical error 
Simulation 
Parameters 
Partitions 1 2 3 4 Total 
% 
Error 
HVL (mm Al) 2.7 6.65 13.9 23.1 N/A N/A 
Collimation Width (cm) 5.4 10.66 16.38 26.6 N/A N/A 
% weighting for each 
steps 
34 33 23 10 100 N/A 
Organ 
Dose 
(mGy) 
Uterus 8.94 18.16 27.23 34.61 18.75 20.22 
Urinary Bladder 4.63 11.59 19.82 26.43 12.6 25.72 
Prostate 6.04 12.85 19.44 25.3 13.3 46.33 
Femeral Head 1.51 4.06 7.77 12.8 4.92 14.34 
Testicles 0.76 1.96 3.68 5.6 2.31 70.1 
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4.1.3 Effect of phantom size measurements 
Organ doses for Standard head and pelvis spot CBCT protocols on the VarianTM unit were 
calculated. To understand the effect of phantom sizes, we have calculated critical organ 
doses using standard Rando phantom size and standard Australian male sizes.  
 
 Head Results  
 
Organ doses for Standard head CBCT protocols on the VarianTM unit were calculated. 
For convenience, the results for both phantom sizes (Rando and Australian standards) are 
displayed in Table 13. The graphical representations of dose comparison along with the 
simulation error were shown in figure 19. 
 
Table 13 Comparison of Organ doses for a head CBCT procedure as determined from simulation using PCXMCTM 
for standard Rando man and standard Australian man 
Organ 
Dose 
obtained 
for 
Standard 
Australian 
man 
simulation 
(mGy) 
% Error in 
Std 
Australian 
man 
Measurement 
Dose 
obtained for 
Standard 
Rando man 
simulation 
(mGy) 
% Error in 
Std rando 
man 
Measurement 
% 
Difference 
between 
standard 
Australian 
man and 
standard 
Rando man 
(%) 
Parotid 
Gland 
4.24 17.79 4.59 17.62 7.62 
spinal 
cord 
upper 
6.87 9.42 7.08 9.95 2.87 
middle  0.05 61.77 0.05 68.35 -7.94 
Lower 0.00 N/A 0.00 N/A N/A 
Skull 10.87 2.9 12.03 3.05 9.69 
Brain 4.80 4.43 5.31 4.37 9.64 
Oral 
Mucosa 
2.97 22.84 3.34 23.26 11.13 
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Figure 19 Graphical Representation of comparison of Organ doses for a head CBCT procedure as determined from 
simulation using PCXMCTM for standard Rando man and standard Australian man 
 
 
 
 Pelvis spot Results 
Organ doses for pelvic spot CBCT protocols on the VarianTM unit were calculated. For 
convenience, the results for both phantom sizes (Rando and Australian standards) are 
displayed in Table 14. The graphical representations of dose comparison along with the 
simulation error were shown in figure 20. 
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Table 14 Comparison of Organ doses for Pelvis Spot CBCT procedure as determined from simulation using 
PCXMCTM for standard Rando man and standard Australian man 
Organ 
Dose 
obtained 
for 
Standard 
Australian 
man 
simulation 
(mGy) 
% Error in 
Std 
Australian 
man 
Measurement 
Dose 
obtained 
for 
Standard 
Rando 
man 
simulation 
(mGy) 
% Error in 
Std rando 
man 
Measurement 
% 
Difference 
between 
standard 
Australian 
man and 
standard 
Rando 
man (%) 
Uterus 15.96 20.67 18.75 20.22 14.88 
Urinary 
Bladder 
10.36 26.55 12.60 25.72 17.76 
Prostate 11.02 47.36 13.30 46.33 17.10 
Femoral 
Head 
4.34 14.30 4.92 14.34 11.64 
Testicles 1.89 72.2 2.31 70.1 18.05 
 
 
 
 
Figure 20   Graphical Representation of comparison of Organ doses for Pelvis Spot CBCT procedure as determined 
from simulation using PCXMCTM for standard Rando man and standard Australian man  
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 TLD Measurements 
  
The Dose measurements for various critical organs were performed using the TLD chips. 
These measurements for Head CBCT and Pelvis spot CBCT protocols were tabulated in 
sections 4.2.1 and 4.2.2. 
4.2.1 Head CBCT Protocol Results 
 
The TLD batch calibration for 100 kV beams was determined. The measured calibration 
factor of 0.0242 mGy/nc units was utilised for the TLD readout into organ dose. See full 
results in Appendix 12. A summary of the organ doses is shown in Table 15. From this 
table, the average organ doses were calculated for parotid, brain, eye and spinal cord. 
Therefore, another table 16 is derived from table 15 and is considered for the further 
comparison. Here only spinal cord (B) values are considered as it exactly replicates 
location of spinal cord in the PCXMCTM simulation. 
Table 15 Summary of organ doses obtained from TLD measurements performed for Head Protocol 
Organ (position*) 
Average position 
Dose (mGy) 
Standard 
Deviation* 
Coefficient of variation 
(%) 
SPINAL 
CORD(T) 
0.71 0.02 2.6 
SPINAL 
CORD(M) 
1.81 0.10 5.4 
SPINAL 
CORD(B) 
5.0 0.2 3.1 
BRAIN (Top) 4.0 0.1 3.6 
BRAIN (M) 3.88 0.2 3.9 
BRAIN (B) 4.43 0.2 5.4 
PAROTID 
GLAND (L) 
5.24 0.1 2.3 
PAROTID 
GLAND (R) 
5.12 0.1 1.3 
EYE (L) 0.91 0.1 14.0 
EYE (R) 1.02 0.02 2.0 
*Standard deviation of the three TLD chip readings 
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Table 16 Table showing Average Organ TLD doses 
Organ  Average TLD Dose (mGy) 
SPINAL CORD* 5.00 
BRAIN  4.10 
PAROTID GLAND  5.18 
EYE  0.97 
*Spinal chord B only (see text) 
 
4.2.2 Pelvic Spot TLD Results 
The TLD batch calibration for 125 kV beams was determined. The obtained calibration 
factor of 0.0273 mGy/nc units was used to convert the TLD reader data using the head 
protocol into an organ dose. See the full results in Appendix 13. A summary of the organ 
doses is seen in Table 17. 
 
Table 17 Summary of organ doses obtained from TLD measurements performed for Pelvis Spot Protocol 
Organ (position*) 
Dose (mGy) 
Standard 
Deviation 
Coefficient of 
variation 
UTERUS 25.28 3 11.2 
F. head Left 15.68 2 10.4 
F. head right 18.24 2 9.1 
Prostate 24.55 4 14.7 
Bladder 23.24 3 12.5 
Bladder plane Left lateral 1 22.46 2 9.0 
Bladder plane Left lateral 2 21.56 1 3.4 
Bladder plane Left lateral 3 16.43 2 12.4 
Bladder plane Left lateral 4 14.85 3 18.9 
Bladder plane Left lateral 5 18.30 2 12.9 
Bladder plane right lateral 5 20.52 2 11.8 
Bladder plane right lateral 4 20.85 0.2 1.2 
Bladder plane right lateral 3 24.80 2 9.3 
Bladder plane right lateral 2 23.87 2 9.0 
Bladder Plane right lateral 1 22.59 3 14.3 
Skin front 30.57 1 3.8 
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5 Discussion 
 
 Comparison between simulation software and TLD measurements 
The comparison between TLD measured results and PCXMCTM simulated results are 
tabulated in table 18 and 19. Also, the graphical representation of the dose comparisons 
is shown in figures 20 and 21. From the comparison table, it can be seen that the measured 
dose to the parotid gland is matching the simulated dose to within 10%. Whereas for the 
spinal cord, a similar comparison sees almost 30% more dose in the simulation. It also 
should be noted that certain organs where additional holes could not be drilled, cannot be 
compared because the Rando phantom TLD chip placements did not match the simulation 
calculated dose from PCXMC. Due to these different scenarios created by TLD 
measurements and PCXMCTM simulations the one to one comparison between TLD 
measurements and PCXMCTM simulations are quite limited as shown in Table 18. 
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Table 18 Comparison of TLD measured organ doses and PCXMCTM simulated organ doses for Head CBCT 
protocol 
Dose Comparison Between PCXMCTM simulated results and TLD measured values for 
Standard Head CBCT protocol 
Organ 
Dose obtained for 
Standard Rando man 
Through simulation 
(mGy) 
Dose Obtained in 
TLD Measurement 
(mGy) (see section 
4.2.1) 
Percentage deviation 
from TLD 
measurement 
Parotid Gland 4.59 5.18 11.41 
spinal cord upper 7.08 5 -41.51 
middle  0.05 N/A N/A 
Lower 0 N/A N/A 
Skull 10.86 N/A N/A 
Brain 4.8 4.43 -8.35 
Oral Mucosa 2.97 N/A N/A 
 
 
 
 
Figure 21   Graphical representation of Comparison of TLD measured organ doses and PCXMCTM simulated organ 
doses for Head CBCT protocol  
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Table 19 Comparison of TLD measured organ doses and PCXMCTM simulated organ doses for Pelvis Spot CBCT 
protocol 
Dose Comparison Between PCXMCTM simulated results and TLD measured values for 
Pelvis Spot CBCT protocol 
Organ 
Dose obtained for 
Standard Rando man 
Through simulation 
(mGy) 
Dose Obtained in 
TLD Measurement 
Percentage deviation 
from TLD 
measurement 
Uterus 18.75 25.28 25.83 
Urinary Bladder 12.6 23.24 45.78 
Prostate 13.3 24.55 45.83 
Femoral Head 4.92 16.96 70.99 
Testicles 2.31 N/A N/A 
 
 
 
Figure 22   Graphical representation of comparison of TLD measured organ doses and PCXMCTM simulated organ 
doses for Pelvis Spot CBCT protocol  
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protocols which rotate through 2000 and use a full fan for the completion of the protocol. 
Because of this 2000 execution, the organs in the area where the 2000 beam passes through 
will give a different dose value in comparison with organs which are not directly in the 
beam path. For example, in the case of the head protocol only one parotid gland is exactly 
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inside the 2000 arc and the other one lies outside the beam arc. As result of this type of 
beam rotation a set of symmetrical organs may produce two different dose values. From 
these measurements, it is also noted that the organ which lies outside the arc received less 
dose than the organ inside the arc. This is because the organ that stays outside will receive 
only scattered radiation. Using this 2000 rotation arc, the entire structure can be 
reconstructed; therefore, this approach is useful in reducing the total dose to the site where 
this type of technique is used.  
 
In the case of PCXMCTM simulation the situation is entirely different. The simulation 
simply averages the entire dose over a pair of organs irrespective of whether it stays left 
or right. It also averages the dose over the entire organ volume. Hence, the dose displayed 
by the simulation is an average of the dose over the entire volume of that organ. For the 
TLD dose measurements, the organ doses are point doses. Therefore, simulation and TLD 
measurements will show a difference in dose values unless many TLDs are used. 
  
5.1.1  Organ dose calculations for a full treatment cycle due to CBCT 
protocols 
It is important to estimate the total organ doses to understand and assess the impact due 
to the CBCT protocols on the entire treatment cycle. As there are no exact values for each 
individual cancer treatment it is done by considering the possible worst-case scenarios.  
 
 Head Protocol 
  
For all head and neck cancer patient cases the international standard for definitive 
treatment is 70 Gy in daily fractions of 2 Gy over seven weeks, although altered 
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fractionation regimens are widely used. The frequency of CBCT imaging varies with each 
specific treatment type. Two examples have been selected, radical brain and radical head 
and neck. 
For a radical brain treatment with a total dose of 70 Gy delivered in fractions of 2 Gy over 
seven weeks can be considered. As per the protocols followed in TCH for a radical brain 
case, daily CBCT is performed. This means that for the entire duration of the treatment 
there will be 35 CBCT procedures (see Table 2). Therefore, the total dose for some of the 
critical organs in head, using measured TLD data is calculated and tabulated in Table 20 
showing that the highest dose is to the period gland, however this dose is < 1% of the 
threshold level.  
 
Table 20 Worst case scenario table showing total organ dose due as determined for to CBCT procedures for a 
radical brain case at TCH 
Critical 
Organ 
Dose per 
CBCT 
(mGy) 
Total 
dose in 
mGy 
Total 
Dose in 
Gy 
Threshold values 
(Gy) (see table 4) 
Spinal cord 5 175 0.175 45 
Brain  4.10 143.6 0.144 60 
Parotid 
gland 
5.18 181.3 0.181 25 
 
 
Similarly, for a radical head and neck cases, the worst-case scenario table is prepared. In 
this case the CBCTs are performed on a weekly basis therefore the total number of CBCT 
procedures during the entire treatment cycle will be seven. Calculation of the total dose 
due to CBCT procedures calculated in Table 21 
 
Table 21 Worst case scenario table showing total organ dose due to CBCT procedures for a radical Head and Neck 
case 
Critical Organ Dose per CBCT (mGy) 
(See section 4.2.1) 
Total dose 
(mGy) 
Total dose 
(Gy) 
Threshold values 
(Gy) (see table 4) 
Spinal cord 5 35 0.035 45 
Brain 4.10 28.7 0.029 60 
Parotid gland 5.18 37.26 0.037 25 
 
 91 | P a g e  
 
 Pelvis Protocol  
  
From the dose calculated for a single pelvic CBCT two worst case scenarios were 
considered for cases performing pelvic CBCT. However, the frequency of CBCT imaging 
varies with specific treatment types. Two examples have been selected, bladder cancer 
and intact prostate.   
 
For a bladder cancer case CBCTs are performed for the first 3 fractions and then weekly 
basis. The typical dose prescriptions for a bladder cancer is 60 -64 Gy in 30-32 fractions 
over 6-6.5 weeks. The worst-case scenario critical organ dose calculation for a bladder 
cancer is shown in Table 22. Here, the typical number of CBCT protocols performed will 
be nine. 
 
Table 22 Worst case scenario table showing total organ dose due to CBCT procedures for a bladder case 
Critical Organ Dose per CBCT 
(mGy) (see 
section 4.2.2) 
Total dose 
(mGy) 
Total Dose (Gy) 
Threshold values 
(Gy) (see table 4) 
Uterus 25.28 227.52 0.228 14-30 Gy[69] 
Femoral Head 16.96 152.54 0.153 V52Gy<10%** 
Prostate 24.55 220.95 0.221 N/A 
**V52Gy<10% - Volume of (organ) receiving 52Gy or more should be less than 10% 
 
 
 
 
Similarly, for an intact prostate CBCT procedures are performed daily for the soft tissue 
match. The critical organ dose calculations for the entire treatment cycle due to CBCT 
procedures are shown in Table 23 showing that the highest dose is to the uterus, however 
this dose is at worst around 6% of the threshold level. 
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Table 23 Worst case scenario table showing total organ dose due to CBCT procedures for an intact prostate case 
Critical Organ Dose per 
CBCT (mGy) 
Total dose 
(mGy) 
Total Dose 
(Gy) 
Threshold values 
(Gy) (see table 4) 
Uterus 25.28 808.96 0.809 14-30 Gy[69] 
Femoral Head 16.96 542.72 0.543 V52Gy<10%** 
Bladder 23.24 743.68 0.744 
V80Gy<15%** 
V75Gy<25%** 
V70Gy<35%** 
V65Gy<50%** 
** V(XX)Gy<10% - Volume of (organ) receiving XX Gy or more should be less than 10% 
 
In all cases it needs to be considered that while the CBCT dose is well below the threshold 
values, these doses will be added to any dose the organ receives as part of the treatment 
and so is by no means the final dose to the organ. 
 
However, these organs may well be getting a significant dose from their MV treatment. 
It is important to recognise that while the total CBCT dose may be < 5% of threshold in 
most cases the dose should be considered when assessing the total of MV and CBCT 
when preparing the treatment plan. Also note that AAPM TG 180 [4] suggests that 
imaging dose should be accounted for in the treatment plan when it exceeds 5% of the 
prescription dose.  
 
It should be noted in practice the number of radiotherapy fractions may vary greatly due 
to a number of patient specific factors such as: 
• Size and location of the cancer 
• Type of cancer 
• The reason for the treatment 
• Patient’s general health  
• Any other concurrent treatments that patient is receiving. 
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For the reasons above the establishment of an absolute total dose due to full fan CBCT 
protocols in radiotherapy is limited. The dose due to a single CBCT procedure is easily 
demonstrated and this can be extended to give the total treatment cycle dose provided the 
total number of fractions and duration of treatment is available. 
 
 
5.1.2 Effective dose calculations using PCXMCTM Software  
Another important aspect of this software was its ability to calculate the effective dose to 
the body. This software can perform effective dose calculations by using ICRP 60 or 
ICRP 103 tissue weighting factors. The effective dose calculations performed by this 
software is displayed in Table 24. All the doses are in mSv. 
 
 
Table 24 effective dose calculated by PCXMCTM software for one CBCT protocol for different phantom sizes and 
regions 
Protocol  Effective dose (mSv) 
Standard Australian man- Pelvis 3.24 
Standard Australian man- Head 0.23 
Standard Rando man- Pelvis 3.78 
Standard Rando man- Head 0.24 
 
As seen in in section 5.1.1., some worst-case treatment scenarios have been chosen to 
display the effective dose due to the entire treatment cycle. For the head protocol, a 
radical-head and radical-head-and-neck case was selected. Similarly, for the pelvic 
bladder cancer, an intact prostate was selected. The effective dose due to the CBCT 
procedures in these cases was calculated from the results obtained in Table 24 and is 
displayed in Table 25. 
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Table 25 Effective dose calculations for some worst case treatment situations 
CBCT Protocol 
Case Phantom 
Effective dose 
(mSv) 
Head 
Radical Brain 
Standard Rando 
man 
8.4 
Standard 
Australian man 
8.05 
Radical head 
and Neck 
Standard Rando 
man 
1.68 
Standard 
Australian man 
1.61 
Pelvis 
Bladder 
Cancer 
Standard Rando 
man 
34.02 
Standard 
Australian man 
29.16 
Intact Prostate 
Standard Rando 
man 
120.96 
Standard 
Australian man 
103.68 
 
 
5.1.3 Reasons for Difference in TLD measurements and PCXMCTM 
simulations 
The following lists present some of the reasons that might have triggered the 
discrepancies between the TLD measurements and the PCXMCTM simulations, apart 
from sampling issue mentioned above (in section 5.1) 
 
In the case of the TLD measurements: 
• Errors in the organ position identification in the Rando phantom. 
• Errors associated with the TLD calibration procedures, for example in 
reviewing the individual calibration factor for each measurement process. 
• Increasing the number of TLD chips allocated for each organ to reduce the 
effect of partial irradiation effects. 
• During the TLD measurements some of the TLD chips might have positioned 
at the radiation beam arc edges. The organs representing the chips may have 
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fallen on the edge or beam boundaries have a tendency to show larger 
discrepancies.   
• The PCXMC simulation does not include the attenuation due to the associated 
fixation devices during treatment. 
 
In the case of the PCXMCTM simulations: 
• It was noticed that the simulated organ using PCXMC were often only 
partially irradiated, hence giving a reduced dose when compared to sampled 
TLD dose measurement. 
• PCXMC is not an exact replica of the RANDO phantom and so under ideal 
condition it cannot be expected to give identical results.  
• The PCXMC simulation does not include the attenuation due to the treatment 
couch during the rotation irradiation. 
•  The PCXMC simulation does not include the attenuation due to the 
associated fixation devices during treatment. 
• During the PCXMCTM simulations the entire region of interest is divided into 
four dose steps and each step is assumed to have different collimation widths 
to repress the effect of Bow-tie filter. For the smallest HVL value small 
collimation widths are predicted but these collimation widths may not have 
been sufficient to cover the organs towards the surface.  
• Omission of the treatment couch in the PCXMC simulation could be a source 
of uncertainty/difference between simulation and TLD results.  
• Use of patient fixation devices such as vacuum bags, breast board, chest 
boards, bellyboards, thermoplastic masks etc. are not able to simulate with 
PCXMC. 
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• Small Errors in the position of the patient, prone and angle of TLD 
measurement might have triggered larger errors in simulation  
 
 Effect of size and weight – A comparison between standard Rando 
man and Standard Australian man 
During the research, we have also performed a dose comparison between standard Rando 
man and standard Australian man. The comparison of doses between the standard 
Australian man and standard Rando man showed that the dose to the standard Australian 
man is significantly lower than the standard Rando man. The dose comparison table 
(Table 17 and 18) shows the critical organs of standard Australian man receives only 82-
88% dose than the standard Rando man for same exposure parameters.  
 
 It also underlines the fact that when performing the Cone beam CT patients of large size 
with more height and weight (cross sectional area), there needs to be higher exposure 
parameters used to obtain more realistic images of adequate quality.   Similarly, for 
smaller patients, parameters could be reduced and still maintain adequate quality. 
Therefore it is necessary to explore the relationship between image quality and imaging 
dose, which may provide guidance for designing optimal low-dose scan protocols for 
various specific IGRT tasks[81]. 
  
The importance CBCT image quality in Radiotherapy has been expressed by Lim et al. 
as “Poor image quality, such as poor soft tissue contrast, will affect the accuracy in image 
registration between the CT reference image and the cone-beam CT image. This will 
result in patient setup errors that can lead to inaccurate treatment delivery” [82]. 
Therefore, it is important to have a minimum good image quality for the CBCT images. 
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Here in CBCT imaging the patient size plays a vital role in image quality. As the patient 
size varies continuously, it is important to optimize the exposure parameters according to 
patient size to achieve the required image quality while minimising the dose to the patient 
and there by satisfying the radiation protection principles. 
 
  General Discussion on Methodologies 
5.3.1 TLD  
For the first part of this research methodology the use of TLDs as a dosimeter was chosen. 
The TLDs are one of the most common radiation dose monitoring pieces of equipment 
used in such cases. Depending on the application and usage there are different types of 
TLDs that have been developed. The TLD used here are LiF: Mg, Ti. It is also known as 
the TLD 100 as a commercial model number by the manufacturer.  The main advantages 
and disadvantages of the TLDs are discussed below. 
 Strengths of TLD measurements 
The strengths of TLD methodologies are detailed below 
 
• TLD chips are small, compact and available in any shape, so can be inserted into 
phantoms or a human body (if suitably protected) for dose measurements. 
• TLD 100 has an effective atomic number close to that of soft human tissue. 
Therefore, the dose delivered to the TLD 100 dosimeters are close to the soft tissue 
dose over a wide dose and energy range relevant to CBCT. 
• TLDs exhibits only limited fading. As result the irradiated TLDs can be stored 
longer. 
• TLDs have a high sensitivity, therefore can be used for measuring low doses. 
• TLD measurements have high precision and accuracy. 
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• TLDs have high stability under standard environmental conditions. 
• TLDs are independent of relative energy. 
 Weaknesses of TLD measurement 
The main weaknesses associated with TLD methodologies are briefly discussed 
below  
 
• TLDs do not provide a permanent record of doses because heating the TLD chip 
for reading the exposure releases the trapped charge that is proportional to the 
deposited energy. Therefore, repeated readings are not possible. 
• Sensitivity to light:  Some of the TLD materials lose their radiation signal when 
exposed to light. This could be a big problem in the case of such TLDs. 
• Many TL materials suffer thermal quenching. As a result, the material loses its 
thermoluminescence efficiency as the temperature of the material increases. 
• TLD process is very time consuming. 
5.3.2 PCXMCTM  
 For the second part of the research methodology the simulation software 
PCXMCTM was used. It is a Monte-Carlo radiation transport-based software. This is one 
of the CT simulation software currently available in the market. Its main pros and cons 
are discussed below 
 Advantages of PCXMCTM software 
 
The advantages associated with the use PCXMCTM software as a simulation tool for 
CBCT are: 
 
• This software utilizes the hermaphrodite phantom model initially created by Cristy 
and Eckerman and later modified by Eckerman and Raymen. 
• It has the option for calculating the organ dose for 27 different organs. 
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• It allows the user to change the patient sizes to make the simulations more realistic. 
• It allows free adjustment of X-ray beams projections and other examination 
conditions of projection radiography and fluoroscopy. 
• Once set up organ dose estimations can be made rapidly. 
• It can calculate the effective dose based on the weighting factors suggested by 
both ICRP-60 and ICRP-103. 
• This program can also be used in calculating the cancer risk estimation due to 
incident radiation. 
 Disadvantages  
The main disadvantages associated with using the PCXMCTM software as a simulation 
tool for CBCT are: 
 
• A Bow-tie filter cannot be simulated directly. It only allows an input of the 
standard flat filter geometry. 
• The simulation of the bow tie filter adds complexity to the simulation, however 
once established, the software can be used rapidly 
• Dose determination of organs can be subject to the partial volume effect and so 
underestimate maximum dose for certain organs. 
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6 Conclusion 
The two main aims of this project were (1) to establish a set of parameters that affect the 
dose to critical organs due to the full fan CBCT protocol using different methodologies 
and (2) to review two methodologies for estimating the dose to critical organs due to full 
fan CBCT protocols. 
The establishment of CBCT dose estimates using measurement protocols through a TLD 
methodology was successfully achieved using a Rando phantom. The results showed 
excellent agreement with the results obtained by pioneers in this field of research (see 
section 5.2).  
 
Some worst-case scenario calculations of organ doses for head and neck case and pelvic 
cases have been calculated. The effect due to CBCT doses were shown to be not 
negligible, and they may be critical in some cases where dose escalation for improved 
tumour control may lead to the organ threshold dose being reached.  
 
The measurement of critical organ dose using the PCXMCTM software through the 
simulation of a Bow-tie filter was attempted using a unique methodology. The doses 
obtained through this newly proposed Bow-tie filter simulation methodology, utilizing 
the PCXMCTM software, showed a variation to the TLD results ranging from 8% to 40% 
for the standard head protocol and 25% to 71% for the pelvis protocol in comparison with 
the TLD measurements. 
 
The comparison of the PCXMCTM software simulation results for the standard Rando 
man phantom and standard Australian man phantom showed almost constant reduction 
between the data, ranging from 5% to 18 %. The Standard Australian man Phantom 
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showed less critical organ doses in comparison with the Standard Rando man Phantom. 
This underlies the fact that as the patient size gets thinner the amount of dose received by 
the critical organs becomes more when exposed under the same exposure parameters[83] 
as is the case when the protocol factors remain constant, independent of patient size, as is 
commonly the case in radiotherapy CBCT implementation. The Bow Tie filter allows the 
exit profile to be more constant. The reason why small patients get a higher dose is more 
complex and involves a longer period of exposure on the input and less attenuation on the 
exit of the beam. [84]. Larger patients require the use of more x-ray photons than do 
smaller patients to achieve similar levels of image quality in x-ray imaging modalities, 
however this principle is often not applied in practice. 
 
Even though the dose due to CBCT protocols has been largely neglected in the calculation 
of radiotherapy treatment doses, the methodologies described in this thesis shows that 
there is an important contribution from the CBCT protocols performed during the 
radiotherapy treatment. In some cases, this may not be critical whereas in some other 
cases these dose contributions due to the CBCT protocols can cause future complications 
particularly secondary cancers or where any other prolonged radiation exposure-related 
effects can occur. 
 
Through this research project work the critical organ doses due to full fan CBCT protocols 
were established. The most challenging component during this entire process was the 
simulation of the Bow-tie filter geometry in the PCXMCTM software. Establishing the 
proper relationship between the HVL values at different positions of the Bow-tie filter 
and its corresponding collimation width was very difficult. After performing so many trial 
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and error methods and using some approximations it was eventually possible to establish 
a relationship between them and hence satisfy one of the major objectives of this project.   
 
Finally, another important aspect, related to the patient risk from CBCT dose, is the 
stochastic effects due to the radiation. From the effective dose calculations (see section 
5.1.2) using the PCXMCTM software it was seen that the effective dose due to these CBCT 
protocols were not negligible in comparison to the natural background radiation typically 
experienced by a person living in Australia. The significance was especially important 
for the case of pelvic protocols where the effective dose was observed to be approximately 
100 times the natural background radiation level. Higher effective doses can raise the 
probability of secondary cancer for patients undergoing these imaging modalities. 
Although several studies [85-87] have been performed in the past to evaluate the 
probability of secondary cancer risk, this area needs more research performed to make 
sure that every effect of radiation can be reliably predicted and used to estimate the risk. 
 
 Future Work and recommendations 
• In order to further establish the usefulness of PCXMCTM it would be good to perform 
modelling without the filter.  In this case, one could run the experiments without the 
filter so as to remove the complications associated with the filter modelling. 
Accounting for the fact that most of the previously conducted studies used no filter 
modelling, the current modelling attempts takes the results closer to reality. To make 
it more similar to reality, it is important to have a more detailed approach in this 
direction. 
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• For greater organ dose accuracy, it would be very useful to increase the number of 
TLDs used to aid in more accurate mapping of organ dose to reduce the effect of partial 
irradiation effects as seen when currently using PCXMC. 
 
• It is important to establish a standard critical organ dose table, resulting from the 
CBCT procedures for future radiotherapy treatments to compare with real-time patient 
measurements. Critical organ doses need to be accurately calculated for future 
treatments to avoid future complications in the patient’s health. It is important to have 
some software available to predict the patient critical organ doses, as the direct 
measurement of the organ dose requires specific protocols that are tedious and 
cumbersome. Therefore, the development of a universally accepted CBCT dose 
calculation software can be, in the future, a routine part of radiotherapy treatment.  
• The important step in the future of radiotherapy treatment is to create a treatment 
planning system which can account for the CBCT dose. Therefore, future work in this 
area must focus on the following aspects, 
➢ Development of an accurate and universal dose prediction methodologies for 
CBCT protocols. 
➢ Development of CBCT dose incorporated treatment planning system 
➢ Investigation of the image quality needed for treatment adjustment including 
tumour size and patient size. 
Developing this sort of system can make sure that the treatment doses do not exceed the 
critical organ threshold doses and thereby assuring that future patient health is not 
compromised.  
• The radiation dose varies significantly with both patient size and tumour position for both 
standard head and pelvic spot scanning protocols. It is therefore recommended that the 
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current practice of using fixed scan parameters, independent of patient size, be 
reconsidered to incorporate patient-specific imaging protocols. This is especially 
important for the case of paediatric patients who can otherwise be expected to receive a 
higher dose. 
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 Appendix 1-  VarianTM  X Ray tube details 
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 Appendix 2 -  CBCT Dosimetry  
The most often used dose indicator with CBCT measurement is CTDI. As per IAEA 
approach the CTDI is defined as  
 
   
 
N*T is the collimated beam width and D(Z) is the dose profile originating from one axial 
rotation along a line that is perpendicular to the tomographic plane, the dose being 
expressed as absorbed dose in air. Typically, the length of integration ‘L’ defined by 
pencil chamber of length 100 mm with CTDI100 forming the basis of CT dosimetry for 
diagnostic applications. As per IAEA human health report series 5 for a beam width 
greater than 40 mm CTDI100 is calculated using the measured CTDI100 in a phantom for a 
reference beam width , corrected by a ratio of CTDIfree-in-air values for the wide beam 
condition relative to the reference condition . The reference beam width should be 20 mm 
or the nearest beam width available is less than 20mm.  
 
Therefore   
 
Where  
CTDI100,ref is the CTDI measured in a phantom for the reference beam width of (N×T)ref; 
using an integration length of 100 mm;  
 
CTDIfree-in-air, N×T is the CTDIfree-in-air for a desired specific value of N×T  
 
CTDIfree-in-air,ref is the CTDIfree-in-air for the reference beam width of (N×T)ref; using an 
integration length of 100 mm. 
 
 
CTDI measurements made in phantom along the central axis and the periphery combined 
to give weighted average of CTDI value by the following equation (18) 
 
 
Where CTDIc is the central dose integral and CTDIp is the average of the peripheral 
integral doses. 
 
To accommodate for couch motion another quantity is defined and is called CTDI vol 
 
CTDI vol  = CTDI w (NT/L) = CTDI w/ P 
 
Where P is the pitch factor = L/NT 
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L is the distance moved by patient per helical rotation between consecutive scans for a 
series of axial scans. 
 To better represent the overall energy delivered by a given scan protocol, the 
absorbed dose can be integrated along the scan length to compute the Dose-Length 
Product (DLP) where 
   
  DLP (mGy-cm) = CTDIvol (mGy) x scan length (cm). 
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 Appendix 3 – Dose profile measurements 
The results of the dose profile measurements are found in Tables 26 and 27 for the full 
bow tie filters associated with the head and pelvis protocols respectively. Note there is a 
1.3% variation in the monitor reading which contributes to the overall dosimetric error 
as discussed in section 5. 
   
Table 26 Beam Profile measurement for 100 kV X-ray beam 
Beam Profile measurements for 100kV 
Chamber position(cm) 
Detector 
(µGy) 
Monitor 
(µGy) 
-10 46.6 28.01 
-8 78.2 28.03 
-6 198.4 28.34 
-4 333.6 28.55 
-2 464.1 28.28 
0 515.4 28.64 
2 463.6 28.47 
4 331.5 28.11 
6 184.9 28.55 
8 68.8 28.31 
10 45.7 28.13 
11 43.9 28.35 
 
 
Table 27 Beam Profile measurements for 125 kV X-ray Beam 
Beam Profile measurements for 125kV 
Distance 
from 
Isocentre(cm) 
Chamber Reading 
 Monitor ( µGy) 
Detector 
(µGy) 
-12 55.53 23.34 
-10 55.67 25.39 
-8 55.59 33.68 
-6 56.14 94.92 
-4 56.15 151.9 
-2 56.24 204.6 
0 55.98 232.7 
2 56.09 215.2 
4 55.55 165.8 
6 55.73 103.8 
8 55.73 40.77 
10 55.64 26.32 
11 55.76 24.25 
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The dose at each point was plotted as a function of distance using Microsoft ExcelTM. A 
polynomial curve fitting equation was then obtained. On integration of this polynomial 
equation the total area under the curve was determined. Dose Profile measurements were 
performed for both 100 kV and 125 kV beams. For the Beam profile measurements, the 
setup used is shown in figure 6.  Dose profiles of 100 kV and 125 kV are shown in figure 
23 and figure 24 respectively. 
 
Figure 23 Dose profile of 100 kV X-ray beam 
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Figure 24 Dose profile of 125  kV X-ray beam 
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 Appendix 4 -  HVL measurements for beam energies of 100 kV 
and 125 kV 
The recorded readings are tabulated in Tables 28 and 29 for the full bow tie filters 
associated with the head and pelvis protocols respectively. 
Table 28 HVL measurements for 100 kV X-ray beam 
Chamber position (cm) Detector (µGy) Monitor (µGy) HVL (mm Al) 
0 314.4 240.2 4.96 
6.3 131.3 239.7 8.04 
8 53.19 240 9.14 
 
Table 29 HVL measurements for 125 kV X-ray beams 
Distance(cm) 
Chamber Reading HVL Value 
(mm Al) Monitor (µGy) Detector (µGy) 
-12 55.53 23.34 10.3 
-10 55.67 25.39 9.89 
-8 55.59 33.68 9.81 
-6 56.14 94.92 8.27 
-4 56.15 151.9 7.08 
-2 56.24 204.6 6.25 
0 55.98 232.7 5.8 
2 56.09 215.2 6.09 
4 55.55 165.8 6.92 
6 55.73 103.8 8.26 
8 55.73 40.77 10.1 
10 55.64 26.32 10.1 
11 55.76 24.25 10.5 
 
 
 The results of chamber position vs HVL values have been plotted with a trend 
line (is obtained with ExcelTM). These are shown in figure 25 for a half profile and as a 
full profile in figure 26 for the bow tie filters associated with the head and pelvis protocols 
respectively. 
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Figure 25 Plot of HVL Vs Chamber position for 100 kV beam 
 
 
Figure 26 Plot of HVL Vs Chamber position for 125 kV beam  
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 Appendix 5 - Tables of position and its corresponding HVL 
Table 30 Table showing HVL corresponds to positional increment of 0.1 cm for 100 kV beam from the isocentre at 
the centre of the Bow-tie filter and increasing across the profile 
Position (cm) HVL (mm Al)  4.1 7.04  8.2 9.14 
0.1 4.98  4.2 7.09 8.3 9.19 
0.2 5.04  4.3 7.14 8.4 9.25 
0.3 5.09  4.4 7.19 8.5 9.30 
0.4 5.14  4.5 7.24 8.6 9.35 
0.5 5.19  4.6 7.29 8.7 9.40 
0.6 5.24  4.7 7.35 8.8 9.45 
0.7 5.29  4.8 7.40 8.9 9.50 
0.8 5.34  4.9 7.45 9 9.55 
0.9 5.40  5 7.50 9.1 9.60 
1 5.45  5.1 7.55 9.2 9.66 
1.1 5.50  5.2 7.60 9.3 9.71 
1.2 5.55  5.3 7.65 9.4 9.76 
1.3 5.60  5.4 7.71 9.5 9.81 
1.4 5.65  5.5 7.76 9.6 9.86 
1.5 5.70  5.6 7.81 9.7 9.91 
1.6 5.75  5.7 7.86 9.8 9.96 
1.7 5.81  5.8 7.91 9.9 10.02 
1.8 5.86  5.9 7.96 10 10.07 
1.9 5.91  6 8.01 
2 5.96  6.1 8.06 
2.1 6.01  6.2 8.12 
2.2 6.06  6.3 8.17 
2.3 6.11  6.4 8.22 
2.4 6.17  6.5 8.27 
2.5 6.22  6.6 8.32 
2.6 6.27  6.7 8.37 
2.7 6.32  6.8 8.42 
2.8 6.37  6.9 8.48 
2.9 6.42  7 8.53 
3 6.47  7.1 8.58 
3.1 6.52  7.2 8.63 
3.2 6.58  7.3 8.68 
3.3 6.63  7.4 8.73 
3.4 6.68  7.5 8.78 
3.5 6.73  7.6 8.83 
3.6 6.78  7.7 8.89 
3.7 6.83  7.8 8.94 
3.8 6.88  7.9 8.99 
3.9 6.94  8 9.04 
4 6.99  8.1 9.09 
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Table 31 Table showing HVL corresponds to positional increment of 0.1 cm for 125 kV beam from the isocentre at the centre 
of the Bow-tie filter and increasing across the profile 
  
Position Total HVL  4 7.03  8.1 9.54 
0 5.72  4.1 7.09  8.2 9.57 
0.1 5.72  4.2 7.16  8.3 9.60 
0.2 5.72  4.3 7.22  8.4 9.63 
0.3 5.72  4.4 7.29  8.5 9.66 
0.4 5.72  4.5 7.35  8.6 9.69 
0.5 5.73  4.6 7.42  8.7 9.71 
0.6 5.73  4.7 7.49  8.8 9.73 
0.7 5.74  4.8 7.55  8.9 9.74 
0.8 5.75  4.9 7.62  9 9.75 
0.9 5.76  5 7.69  9.1 9.76 
1 5.78  5.1 7.76  9.2 9.77 
1.1 5.80  5.2 7.83  9.3 9.77 
1.2 5.81  5.3 7.90  9.4 9.77 
1.3 5.83  5.4 7.96  9.5 9.77 
1.4 5.86  5.5 8.03  9.6 9.76 
1.5 5.88  5.6 8.10  9.7 9.74 
1.6 5.91  5.7 8.17  9.8 9.73 
1.7 5.94  5.8 8.24  9.9 9.71 
1.8 5.97  5.9 8.31  10 9.68 
1.9 6.00  6 8.38  10.1 9.65 
2 6.03  6.1 8.44  10.2 9.62 
2.1 6.07  6.2 8.51  10.3 9.58 
2.2 6.10  6.3 8.57  10.4 9.54 
2.3 6.14  6.4 8.64  10.5 9.49 
2.4 6.18  6.5 8.70  10.6 9.44 
2.5 6.23  6.6 8.77  10.7 9.39 
2.6 6.27  6.7 8.83  10.8 9.33 
2.7 6.31  6.8 8.89  10.9 9.26 
2.8 6.36  6.9 8.95  11 9.19 
2.9 6.41  7 9.01  11.1 9.11 
3 6.46  7.1 9.06  11.2 9.03 
3.1 6.51  7.2 9.12  11.3 8.95 
3.2 6.56  7.3 9.17  11.4 8.86 
3.3 6.62  7.4 9.23  11.5 8.76 
3.4 6.67  7.5 9.28  11.6 8.66 
3.5 6.73  7.6 9.32  11.7 8.55 
3.6 6.79  7.7 9.37  11.8 8.44 
3.7 6.85  7.8 9.42  11.9 8.32 
3.8 6.91  7.9 9.46  12 8.20 
3.9 6.97  8 9.50    
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 Appendix 6 – Steps involved in PCXMCTM ExcelTM Macro 
operation 
The ExcelTM sheet uses three macros for the dose calculation. There was limited 
documentation on the software operation, so a period of familiarisation with the software 
was needed for implantation. The first macro is used as the input parameters of CBCT 
procedure. When running the first script we need to press CTRL (a). The macro asks for 
the number of rows that need to be calculated. As we have 69 angles to calculate we need 
to enter the 69 rows and the destination folder. The macro will then write one definition 
file for each data row in the specified subfolder. 
To execute the next script CTRL (b) needs to be pressed. Again, the macro will ask for 
the rows and subfolder names. The macro will then automatically calculate the specified 
patient doses using the “autocalc”: mode of PCXMCTM rotation 2.0. 
When CTRL (d) is pressed, the macro will again ask which rows of the examination data 
should be processed and the name of the subfolder that was used in the previous steps. 
The macro will then read the calculated doses to the cells in the examination data sheet. 
A screen shot This ExcelTM is Given in Figure 27 
 
 
 
Figure 27 Screen shot  rotation ExcelTM  sheet for calculation 
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 Appendix 7 -The Alderson radiotherapy Phantom Features 
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 Appendix 8 – Standard Australian Man Data from Australian 
Bureau of statistics 
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 Appendix 9 – Screen Shots of LINAC console sowing gantry 
rotation 
 The following images shows the screenshot of console before  and after 
execution of CBCT protocol.  
 
 
 
 
Figure 28 Screenshots of linac console showing the gantry rotation before and after the execution of CBCT 
protocol 
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 Appendix 10– TLD Calibration Form of 100 kV X-ray beam 
Table 32 TLD calibration form of 100 kV X-ray Beam 
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 Appendix 11 – TLD calibration form of 125 kV X-ray Beam 
 
Table 33 TLD calibration  form of 125 kV X-ray Beam 
TLD Calibration Form 
         
I) Background 
information         
         
Date of calibration 
26/07/2017 
 Names of tester(s) 
Ajay Thomas, Helen 
Gustafsson and Corban 
Neeley 
       
  
TLD calibration Names   
  
 Detector Unfors 2 sn 180221 Monitor  Unfors 1 sn 180221 
 
Calibration 
date 
26/09/2016 
 
  
Calibration date 
16/07/2013 
 
 26/09/2016 
II) Irradiation          
         
 
Time of 
irradiation: 6:30:00 PM      
         
 
X-ray 
source: 
VarianTM trilogy Linac LA3 kV CBCT , OBI V 
1.6     
           
         
III) Geometrical setup using the substitution method        
         
 SDD: 100 cm      
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S-monitor-
D: 100 cm 
FS at 
detector: 26.6 × 20 cm 
         
IV) Reading         
 
nominal 
kV= 125       
 
measured 
kV= 123.3 123.7 124.3     
 time 20s       
 ma 80       
 mAs= 32       
 
added 
Filter= 0       
 HVL= 5.93       
 
Detector 
(mGy) Monitor (mGy) ratio      
1 91.910 78.270 1.174      
2 58.120 49.520 1.174      
3 99.970 85.180 1.174      
Average 83.333 70.990 1.174      
 sdd = 79cm  
inverse 
square 
correction 
factor 1.60    
         
TLD calibration 
monitor reading 
(mGy) 
171.517 91.190 
      
         
cal-bkg (nC) 6107.2        
 6040.5        
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 6109.7        
 6925.2        
 6849.6        
 6615.2        
 5540.9        
 7023.7        
 5420.3        
av 6292.5        
std 592.3        
cov% 9.4        
cal factor 
(mGy/nC)  
air kerma / 
charge 
0.0273        
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 Appendix 12 -  TLD Measurements for Head CBCT protocol 
 
 
Table 34 TLD measurements for Head CBCT Protocol 
  
calibration 
factor(mGy/nc) 
0.0242 
air kerma to 
water 
conversion 
1.07 
final 
conversio
n factor 
(mGy/nC) 
0.0259    
Storage 
Index 
Status   
Charge 
(nC) 
ID cal corrected nC nC-bkg mGy   av Position  
A1 measurement 27.399 1.06 29.01 27.53 0.71 Av 0.71 SPINAL CORD 
A2 measurement 32.588 0.90 29.37 27.89 0.72 sd 0.02 SPINAL CORD 
A3 measurement 26.761 1.05 28.01 26.53 0.69 cov 2.6 SPINAL CORD 
A4 measurement 71.227 1.06 75.40 73.92 1.91 Av 1.81 SPINAL CORD 
A5 measurement 86.316 0.82 70.68 69.20 1.79 sd 0.10 SPINAL CORD 
A6 measurement 64.671 1.05 67.90 66.43 1.72 cov 5.4 SPINAL CORD 
A7 measurement 169.890 1.19 201.45 199.98 5.18 Av 5.00 SPINAL CORD 
A8 measurement 214.290 0.89 191.53 190.06 4.92 sd 0.16 SPINAL CORD 
A9 measurement 174.913 1.09 190.42 188.94 4.89 cov 3.1 SPINAL CORD 
A10 measurement 160.488 0.96 153.35 151.87 3.93 Av 4.00 BRAIN  
B1 measurement 164.574 0.92 152.02 150.55 3.90 sd 0.14 BRAIN  
B2 measurement 179.527 0.90 162.31 160.83 4.16 cov 3.6 BRAIN  
B3 measurement 167.548 0.87 145.08 143.60 3.72 Av 3.88 BRAIN  
B4 measurement 149.353 1.02 152.64 151.16 3.91 sd 0.15 BRAIN  
B5 measurement 162.440 0.96 156.52 155.04 4.01 cov 3.9 BRAIN  
B6 measurement 155.766 1.05 163.42 161.95 4.19 Av 4.43 BRAIN  
B7 measurement 171.665 1.00 172.14 170.67 4.42 sd 0.24 BRAIN  
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B8 measurement 181.544 1.00 182.02 180.54 4.67 cov 5.4 BRAIN  
B9 measurement 214.375 0.97 207.08 205.61 5.32 Av 5.24 PAROTID 
B10 measurement 188.211 1.09 205.77 204.29 5.29 sd 0.12 PAROTID 
C1 measurement 244.630 0.81 198.37 196.89 5.10 cov 2.3 PAROTID 
C2 measurement 171.83 1.15 197.61 196.14 5.08 Av 5.12 PAROTID 
C3 measurement 233.87 0.84 196.45 194.98 5.05 sd 0.09 PAROTID 
C4 measurement 199.04 1.02 203.02 201.55 5.22 cov 1.3 PAROTID 
C5 measurement 36.435 0.89 32.53 31.06 0.80 Av 0.91 EYE 
C6 measurement 29.915 1.17 35.15 33.67 0.87 sd 0.13 EYE 
C7 measurement 47.157 0.89 42.02 40.55 1.05 cov 14.0 EYE 
C8 measurement 0.577 0.97 0.56 -0.91 -0.02 Av 1.02 EYE 
C9 measurement 42.939 0.94 40.44 38.97 1.01 sd 0.02 EYE 
C10 measurement 38.459 1.08 41.56 40.09 1.04 cov 2.0 EYE 
D1 Calibration 99.591 1.04 103.68 102.21 2.65 Av 2.54 NA  
D2 Calibration 88.660 1.11 98.61 97.13 2.52 sd 0.07   
D3 Calibration 110.986 0.91 101.33 99.85 2.59 cov 2.8   
D4 Calibration 92.084 1.07 98.23 96.75 2.51       
D5 Calibration 103.968 0.93 96.68 95.20 2.47       
D6 Calibration 84.293 1.02 85.73 84.25 2.18 Av 2.20   
D7 Calibration 91.321 0.94 85.78 84.30 2.18 sd 0.02   
D8 Calibration 90.542 0.96 87.28 85.80 2.22 cov 1.0   
D9 Calibration 100.147 0.86 85.79 84.31 2.18      
D10 Calibration 98.347 0.89 87.34 85.86 2.22      
E1 Calibration 70.685 0.96 67.68 66.21 1.71 Av 1.69   
E2 Calibration 60.516 1.03 62.16 60.69 1.57 sd 0.07   
E3 Calibration 71.118 0.98 69.81 68.34 1.77 cov 4.3   
E4 Calibration 63.716 1.05 67.12 65.64 1.70      
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E5 Calibration 60.803 1.09 66.38 64.90 1.68      
E6 Background 1.427 1.12 1.60 0.13 0.00 Av 0.00   
E7 Background 1.358 1.07 1.45 -0.02 0.00 sd 0.01   
E8 Background 1.671 1.10 1.84 0.36 0.01 cov N/A   
E9 Background 0.764 1.16 0.88 -0.59 -0.02       
E10 Background 1.481 1.08 1.60 0.13 0.00       
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 Appendix 13   - TLD measurements for Pelvis Spot Protocol 
 
Table 35  TLD measurements for Pelvis Protocol 
                    
  
calibration factor (air 
kerma / charge) 
(mGy/nC) 
0.0273 
air kerma to 
water 
conversion 
1.07 
final 
conversion 
factor 
(mGy/nC) 
0.029      
Storage 
Index 
status 
Charge 
(nC) 
ID cal corrected nC nC-bkg 
Dose in 
water 
(mGy) 
  av   
A1 measurement 810.543 0.94 765.74 761.282 22.20 Av 25.28 
UTERUS 
A2 measurement 865.474 1.03 890.60 886.143 25.84 sd 2.83 
A3 measurement 913.608 1.05 957.03 952.571 27.78 cov 11.2 
A4 measurement 509.546 0.94 478.51 474.047 13.83 Av 15.68 
F. head Left 
A5 measurement 554.655 1.05 584.03 579.571 16.90 sd 1.63 
A6 measurement 575.603 0.98 563.42 558.956 16.30 cov 10.4 
A7 measurement 591.637 0.96 567.03 562.570 16.41 Av 18.24 
F. head right 
A8 measurement 647.954 1.05 677.45 672.991 19.63 sd 1.65 
A9 measurement 658.513 0.98 644.60 640.139 18.67 cov 9.1 
A10 measurement 832.169 0.99 825.01 820.547 23.93 Av 24.55 
prostate 
B1 measurement 926.323 1.06 978.92 974.461 28.42 sd 3.60 
B2 measurement 781.047 0.94 735.03 730.570 21.31 cov 14.7 
B3 measurement 803.196 0.98 784.81 780.348 22.76 Av 23.24 
Bladder 
B4 measurement 743.254 0.96 710.83 706.376 20.60 sd 2.90 
B5 measurement 850.417 1.07 907.78 903.322 26.35 cov 12.5 
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B6 measurement 702.570 0.99 694.63 690.169 20.13 Av 22.46 
Bladder plane 
Left lateral  1 
B7 measurement 784.630 1.04 818.86 814.400 23.75 sd 2.02 
B8 measurement 766.251 1.06 809.76 805.297 23.49 cov 9.0 
B9 measurement 748.246 1.03 771.30 766.838 22.37 Av 21.56 
Bladder plane 
Left lateral 2 
B10 measurement 747.999 0.99 737.56 733.103 21.38 sd 0.73 
C1 measurement 748.510 0.97 722.53 718.071 20.94 cov 3.4 
C2 measurement 586.554 0.93 545.52 541.061 15.78 Av 16.43 
Bladder plane 
Left lateral 3 
C3 measurement 524.739 0.97 511.33 506.869 14.78 sd 2.04 
C4 measurement 635.771 1.02 646.04 641.583 18.71 cov 12.4 
C5 measurement 484.516 1.01 490.56 486.104 14.18 Av 14.85 
Bladder plane 
Left lateral 4 
C6 measurement 455.590 0.95 431.21 426.748 12.45 sd 2.80 
C7 measurement 582.169 1.06 619.00 614.538 17.92 cov 18.9 
C8 measurement 707.841 1.02 725.35 720.894 21.03 Av 18.30 
Bladder plane 
Left lateral 5 
C9 measurement 613.599 0.95 584.54 580.079 16.92 sd 2.36 
C10 measurement 589.312 0.99 585.93 581.467 16.96 cov 12.9 
D1 measurement 718.705 0.99 713.25 708.792 20.67 Av 20.52 
Bladder plane 
right lateral 5 
D2 measurement 666.403 0.93 622.80 618.339 18.03 sd 2.42 
D3 measurement 782.260 1.01 788.28 783.820 22.86 cov 11.8 
D4 measurement 6249.686 0.95 5913.14 5908.683 172.33 Av 20.85 
Bladder plane 
right lateral 4 
D5 measurement 707.403 1.01 713.09 708.635 20.67 sd 0.26 
D6 measurement 714.627 1.02 725.56 721.106 21.03 cov 1.2 
D7 measurement 757.538 1.01 764.30 759.838 22.16 Av 24.80 
Bladder plane 
right lateral 3 
D8 measurement 870.120 1.02 889.40 884.940 25.81 sd 2.30 
D9 measurement 883.276 1.03 910.30 905.842 26.42 cov 9.3 
D10 measurement 835.258 1.00 832.59 828.131 24.15 Av 23.87 
Bladder plane 
right lateral 2 
E1 measurement 786.552 0.95 744.64 740.184 21.59 sd 2.15 
E2 measurement 844.139 1.06 891.22 886.757 25.86 cov 9.0 
E3 measurement 801.135 0.93 746.30 741.843 21.64 Av 22.59 
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E4 measurement 837.449 1.08 902.44 897.980 26.19 sd 3.23 Bladder Plane 
right lateral 1 E5 measurement 745.602 0.92 688.46 684.003 19.95 cov 14.3 
E6 measurement 116.240 0.93 108.09 103.634 3.02 Av 21.53 
Skin front 
E7 measurement 1186.230 0.93 1097.36 1092.899 31.88 sd 16.06 
E8 measurement 1107.323 0.92 1022.16 1017.703 29.68 cov 74.6 
E9 Background 3.326 0.93 3.09 -1.366 -0.04 Av 0.00 
Background 
E10 Background 4.675 0.92 4.31 -0.153 0.00 sd 0.02 
F1 Background 5.601 0.92 5.16 0.697 0.02 cov ####### 
F2 Background 5.326 0.93 4.93 0.471 0.01     
F3 Background 4.462 1.08 4.81 0.351 0.01     
F4 Background 9.292 1.07 9.96 5.497 0.16     
 
 140 | P a g e  
 
 Appendix 14   - Simulation of Bow tie filter and subsequent organ dose calculation for standard Australian man 
The Bow-tie filter is simulated using a step approximation and organ doses at each step were calculated using the PCXMCTM rotation 2.0 
ExcelTM sheet. The detailed calculation charts for rando man head given in table 11. The simulation was done using 100 kV beam with a 
reference dose per simulation projection of 0.172 mGy. The associated statistical error from the Monte Carlo simulation program is also 
included. 
 
Table 36 Organ dose calculations for standard Australian man Head Protocol Using PCXMCTM simulation with combined statistical error 
Simulation Parameters 
 Partitions 1 2 3 4 Total % error 
HVL (mm Al) 3.8 8.92 19.1 23.1 N/A N/A 
Collimation Width (cm) 5.2 10.2 14.4 26.6 N/A N/A 
% weighting for each step 34 33 23 10 100 N/A 
Organ Dose (mGy) 
Parotid Gland 1.66 4.02 6.55 8.43 4.24 17.79 
spinal cord upper 3.98 7.31 9.22 9.84 6.87 9.42 
Spinal cord middle  0.02 0.05 0.08 0.10 0.05 61.77 
Spinal cord lower 0 0 0 0 0 N/A 
Skull 4.42 10.62 16.54 20.57 10.87 2.9 
Brain 2.00 4.83 7.32 8.37 4.80 4.43 
Oral Mucosa 0.96 2.79 4.77 6.26 2.97 22.84 
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Similarly, for the pelvis the detailed calculation chart is given in Table 12. The simulation was done using 125 kV beam with a reference 
dose per simulation projection of 1.091 mGy 
 
 
Table 37 Organ dose calculation for Australian man Pelvis Spot protocol using PCXMCTM simulation with combined statistical error 
Simulation Parameters 
Partitions 1 2 3 4 Total % Error 
HVL (mm Al) 2.7 6.65 13.9 23.1 N/A N/A 
Collimation Width (cm) 5.4 10.66 16.38 26.6 N/A N/A 
% weighting for each steps 34 33 23 10 100 N/A 
Organ Dose (mGy) 
Uterus 7.40 15.27 23.28 30.53 15.96 20.67 
Urinary Bladder 3.67 9.27 16.41 22.84 10.36 26.55 
Prostate 4.75 10.53 16.24 21.95 11.02 47.36 
Femeral Head 1.32 3.53 6.80 11.68 4.35 14.30 
Testicles 0.61 1.59 2.96 4.81 1.89 72.22 
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 Appendix 15   - Simulation Error Calculations 
 
The simulation error calculations were performed in the following manner. PXCMC calculated the statistical error for absorbed energies as one 
standard deviation in percentage each organ dose for one partitions were obtained from the simulation excel sheet and shown in Table 38. In order 
to determine the statistical error for each organ for the entire simulation, the associated errors for each projection need to be combined. This was 
done using quadrature summation.  
Table 38 statistical error for absorbed energies as one standard deviation in percentage each organ dose for one partition 1 in the head simulation 
Salivary 
glands 
error 
(%)   
upper 
spine 
Error(%)   
middle 
spine 
error 
(%)   
Lower 
spine 
error %   
skull 
error(%)   
Brain 
error 
(%)   
Oral 
mucosa 
error 
(%)  
1.10 1.21 1.20 1.44 8.30 68.89 94.00 8836.00 0.30 0.09 0.50 0.25 2.10 4.41 
1.10 1.21 1.50 2.25 10.50 110.25 94.00 8836.00 0.30 0.09 0.50 0.25 2.10 4.41 
1.10 1.21 1.00 1.00 9.40 88.36 100.00 10000.00 0.30 0.09 0.50 0.25 1.90 3.61 
1.20 1.44 1.10 1.21 8.40 70.56 100.00 10000.00 0.30 0.09 0.50 0.25 2.40 5.76 
1.20 1.44 1.30 1.69 9.90 98.01 100.00 10000.00 0.30 0.09 0.40 0.16 1.90 3.61 
1.00 1.00 1.50 2.25 8.50 72.25 0.00 0.00 0.30 0.09 0.50 0.25 2.00 4.00 
1.20 1.44 1.40 1.96 8.10 65.61 66.60 4435.56 0.30 0.09 0.50 0.25 2.50 6.25 
1.00 1.00 1.10 1.21 9.80 96.04 54.20 2937.64 0.30 0.09 0.50 0.25 2.10 4.41 
1.00 1.00 1.40 1.96 9.90 98.01 92.80 8611.84 0.30 0.09 0.40 0.16 2.20 4.84 
1.20 1.44 1.30 1.69 9.40 88.36 0.00 0.00 0.30 0.09 0.40 0.16 2.20 4.84 
1.20 1.44 1.20 1.44 6.70 44.89 0.00 0.00 0.30 0.09 0.50 0.25 2.10 4.41 
1.50 2.25 1.10 1.21 9.30 86.49 86.50 7482.25 0.30 0.09 0.40 0.16 2.30 5.29 
1.60 2.56 1.00 1.00 9.40 88.36 0.00 0.00 0.40 0.16 0.40 0.16 2.10 4.41 
1.50 2.25 0.90 0.81 7.80 60.84 0.00 0.00 0.40 0.16 0.40 0.16 2.30 5.29 
1.80 3.24 1.10 1.21 11.00 121.00 0.00 0.00 0.40 0.16 0.50 0.25 2.30 5.29 
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1.90 3.61 1.10 1.21 9.00 81.00 63.80 4070.44 0.30 0.09 0.50 0.25 2.20 4.84 
2.40 5.76 0.80 0.64 8.80 77.44 100.00 10000.00 0.30 0.09 0.40 0.16 2.80 7.84 
2.40 5.76 0.90 0.81 9.80 96.04 0.00 0.00 0.30 0.09 0.50 0.25 2.70 7.29 
3.10 9.61 1.10 1.21 7.70 59.29 86.90 7551.61 0.40 0.16 0.50 0.25 2.40 5.76 
2.90 8.41 0.90 0.81 7.10 50.41 0.00 0.00 0.30 0.09 0.40 0.16 3.30 10.89 
2.40 5.76 0.90 0.81 8.60 73.96 0.00 0.00 0.30 0.09 0.50 0.25 3.40 11.56 
2.10 4.41 0.80 0.64 7.50 56.25 0.00 0.00 0.40 0.16 0.50 0.25 3.10 9.61 
2.40 5.76 0.80 0.64 7.90 62.41 0.00 0.00 0.30 0.09 0.60 0.36 3.00 9.00 
2.40 5.76 0.90 0.81 7.60 57.76 0.00 0.00 0.30 0.09 0.50 0.25 2.60 6.76 
2.10 4.41 1.10 1.21 8.10 65.61 0.00 0.00 0.40 0.16 0.40 0.16 3.30 10.89 
2.60 6.76 0.80 0.64 7.60 57.76 0.00 0.00 0.30 0.09 0.40 0.16 3.10 9.61 
3.00 9.00 1.00 1.00 6.20 38.44 0.00 0.00 0.30 0.09 0.40 0.16 2.70 7.29 
2.70 7.29 0.80 0.64 8.30 68.89 0.00 0.00 0.40 0.16 0.50 0.25 3.40 11.56 
2.80 7.84 1.00 1.00 7.20 51.84 73.10 5343.61 0.30 0.09 0.60 0.36 2.50 6.25 
2.40 5.76 0.70 0.49 6.20 38.44 100.00 10000.00 0.30 0.09 0.50 0.25 3.00 9.00 
3.30 10.89 0.90 0.81 7.20 51.84 66.00 4356.00 0.30 0.09 0.40 0.16 3.30 10.89 
2.60 6.76 0.70 0.49 6.60 43.56 78.40 6146.56 0.30 0.09 0.40 0.16 3.10 9.61 
2.80 7.84 0.80 0.64 5.90 34.81 70.40 4956.16 0.30 0.09 0.30 0.09 3.50 12.25 
2.60 6.76 0.80 0.64 7.30 53.29 100.00 10000.00 0.20 0.04 0.40 0.16 3.40 11.56 
2.60 6.76 0.90 0.81 7.40 54.76 100.00 10000.00 0.30 0.09 0.50 0.25 3.70 13.69 
2.70 7.29 0.60 0.36 7.20 51.84 79.40 6304.36 0.30 0.09 0.50 0.25 3.30 10.89 
2.60 6.76 0.80 0.64 6.00 36.00 0.00 0.00 0.30 0.09 0.50 0.25 2.90 8.41 
2.30 5.29 0.70 0.49 7.10 50.41 0.00 0.00 0.30 0.09 0.40 0.16 3.20 10.24 
2.90 8.41 0.70 0.49 6.60 43.56 0.00 0.00 0.30 0.09 0.50 0.25 3.00 9.00 
2.70 7.29 0.80 0.64 6.70 44.89 96.60 9331.56 0.40 0.16 0.50 0.25 3.60 12.96 
2.80 7.84 0.90 0.81 6.90 47.61 96.60 9331.56 0.40 0.16 0.50 0.25 3.50 12.25 
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3.20 10.24 0.80 0.64 7.40 54.76 99.10 9820.81 0.30 0.09 0.40 0.16 3.00 9.00 
2.50 6.25 0.70 0.49 8.00 64.00 100.00 10000.00 0.30 0.09 0.40 0.16 3.40 11.56 
2.90 8.41 0.70 0.49 8.50 72.25 0.00 0.00 0.30 0.09 0.50 0.25 3.50 12.25 
2.30 5.29 0.80 0.64 7.50 56.25 0.00 0.00 0.40 0.16 0.50 0.25 2.90 8.41 
2.70 7.29 0.70 0.49 8.90 79.21 0.00 0.00 0.30 0.09 0.50 0.25 3.00 9.00 
2.70 7.29 0.70 0.49 8.50 72.25 0.00 0.00 0.30 0.09 0.50 0.25 2.70 7.29 
3.10 9.61 0.70 0.49 7.00 49.00 0.00 0.00 0.30 0.09 0.40 0.16 3.20 10.24 
2.30 5.29 0.80 0.64 6.80 46.24 0.00 0.00 0.30 0.09 0.40 0.16 3.10 9.61 
2.30 5.29 0.80 0.64 5.00 25.00 0.00 0.00 0.30 0.09 0.40 0.16 2.90 8.41 
2.80 7.84 1.00 1.00 6.90 47.61 100.00 10000.00 0.30 0.09 0.50 0.25 2.50 6.25 
2.70 7.29 0.90 0.81 7.70 59.29 100.00 10000.00 0.30 0.09 0.40 0.16 2.70 7.29 
2.10 4.41 1.00 1.00 7.10 50.41 100.00 10000.00 0.40 0.16 0.50 0.25 3.00 9.00 
2.50 6.25 1.00 1.00 6.40 40.96 0.00 0.00 0.30 0.09 0.50 0.25 2.50 6.25 
2.40 5.76 0.90 0.81 5.40 29.16 0.00 0.00 0.40 0.16 0.50 0.25 2.90 8.41 
2.40 5.76 0.90 0.81 6.80 46.24 0.00 0.00 0.30 0.09 0.50 0.25 2.70 7.29 
2.30 5.29 0.80 0.64 8.10 65.61 0.00 0.00 0.30 0.09 0.50 0.25 2.60 6.76 
2.50 6.25 0.70 0.49 7.20 51.84 0.00 0.00 0.30 0.09 0.50 0.25 2.70 7.29 
2.40 5.76 1.00 1.00 8.00 64.00 0.00 0.00 0.30 0.09 0.50 0.25 2.80 7.84 
2.20 4.84 0.90 0.81 7.80 60.84 0.00 0.00 0.30 0.09 0.50 0.25 2.70 7.29 
1.80 3.24 1.00 1.00 7.70 59.29 100.00 10000.00 0.30 0.09 0.40 0.16 2.70 7.29 
1.60 2.56 1.00 1.00 6.70 44.89 0.00 0.00 0.30 0.09 0.40 0.16 2.50 6.25 
1.60 2.56 0.90 0.81 9.70 94.09 0.00 0.00 0.40 0.16 0.40 0.16 2.40 5.76 
1.50 2.25 1.10 1.21 8.30 68.89 0.00 0.00 0.30 0.09 0.50 0.25 2.60 6.76 
1.40 1.96 1.20 1.44 8.60 73.96 0.00 0.00 0.30 0.09 0.40 0.16 3.00 9.00 
1.30 1.69 1.00 1.00 11.20 125.44 93.40 8723.56 0.30 0.09 0.50 0.25 2.80 7.84 
1.20 1.44 1.20 1.44 8.20 67.24 92.90 8630.41 0.30 0.09 0.50 0.25 2.70 7.29 
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1.20 1.44 1.10 1.21 8.30 68.89 100.00 10000.00 0.30 0.09 0.50 0.25 2.40 5.76 
1.00 1.00 1.20 1.44 8.70 75.69 0.00 0.00 0.30 0.09 0.50 0.25 2.00 4.00 
Sum of 
squares 344.47  65.64  4419.33  255705.93  7.07  15.06  540.12 
Quadrature 
sum 18.56  8.10  66.48  505.67  2.66  3.88  23.24 
 
Similarly, the error data obtained for each partition of Head and pelvis protocols of standard Rando man and standard Australian man.  
  
